<!DOCTYPE html> <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema - Mehta, H - 2018 | Cochrane Library</title> <meta property="og:title" content="Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema - Mehta, H - 2018 | Cochrane Library" /> <meta property="og:url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011599.pub2/references" /> <meta property="og:type" content="article" /> <meta property=”og:image” content=”https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png” /> <meta content="initial-scale=1.0, width=device-width" name="viewport" /> <meta name="dc.identifier" scheme="DOI" content="10.1002/14651858.CD011599.pub2" /> <meta name="citation_title" content="Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema" /> <meta name="citation_author" content="Hemal Mehta" /> <meta name="citation_author_email" content="hm@cantab.net" /> <meta name="citation_author" content="Charles Hennings" /> <meta name="citation_author_institution" content="Royal Free London NHS Foundation Trust" /> <meta name="citation_author" content="Mark C Gillies" /> <meta name="citation_author_institution" content="University of Sydney" /> <meta name="citation_author" content="Vuong Nguyen" /> <meta name="citation_author_institution" content="University of Sydney" /> <meta name="citation_author" content="Anna Campain" /> <meta name="citation_author_institution" content="University of Sydney" /> <meta name="citation_author" content="Samantha Fraser‐Bell" /> <meta name="citation_author_institution" content="University of Sydney" /> <meta name="citation_journal_title" content="Cochrane Database of Systematic Reviews" /> <meta name="citation_publisher" content="John Wiley &amp; Sons, Ltd" /> <meta name="citation_issue" content="4" /> <meta name="citation_doi" content="10.1002/14651858.CD011599.pub2" /> <meta name="citation_date" content="2018" /> <meta name="citation_online_date" content="2018/04/18" /> <meta name="citation_abstract_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011599.pub2/abstract" /> <meta name="citation_fulltext_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011599.pub2/full" /> <meta name="citation_pdf_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011599.pub2/pdf/CDSR/CD011599/CD011599.pdf" /> <meta name="citation_issn" content="1465-1858" /> <meta name="citation_language" content="en" /> <meta name="citation_keywords" content="Bevacizumab [*therapeutic use]; Dexamethasone [*therapeutic use]; Diabetic Retinopathy [*drug therapy, etiology, surgery]; Drug Therapy, Combination [methods]; Glucocorticoids [*therapeutic use]; Intraocular Pressure; Intravitreal Injections; Macula Lutea [drug effects]; Macular Edema [*drug therapy, etiology, surgery]; Randomized Controlled Trials as Topic; Ranibizumab [*therapeutic use]; Receptors, Vascular Endothelial Growth Factor [antagonists &amp; inhibitors]; Triamcinolone [*therapeutic use]; Vascular Endothelial Growth Factor A [*antagonists &amp; inhibitors]; Visual Acuity [drug effects]" /> <script type="text/javascript" src="//script.crazyegg.com/pages/scripts/0056/6375.js" async="async"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <script type="text/javascript">var o={auth:{customerIds:["P#DRAAEAC","EAL00000056729","DRAA3TITLES","TSINGH009S","EAL0001468","EAL00000045347"],individualId:null,brandedCustomer:"EAL0001468",roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=UTF-8" http-equiv="content-type" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/favicon.ico" rel="Shortcut Icon" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" rel="canonical" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-CN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh_TW&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-TW" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;hr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="hr-HR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="x-default" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="en-US" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fr-FR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;de&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="de-DE" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ja&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ja-JP" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ko&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ko-KR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ms&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ms-MY" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fa&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fa-IR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pl&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pl-PL" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pt&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pt-PT" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ru&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ru-RU" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;es&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="es-ES" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ta&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ta-IN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;th&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="th-TH" rel="alternate" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;aui&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link href="&#x2f;html&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1513680834000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718256000" rel="stylesheet" type="text/css" /> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 13},getRevision:function(){return"605.1"},getVersion:function(){return"13.0"},isAir:function(){return false},isChrome:function(){return false},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return false},isMac:function(){return true},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EfT7x5RD";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dreferences\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011599\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011599\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article References"},article:{availableLanguage:["en","es","ru","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011599.pub2",title:"Anti\\u2010vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema",firstPublishedDate:"Apr 18, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;custom&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <style type="text/css"></style> <script src="//assets.adobedtm.com/6e626c9ec247e474f6b98eb15a79a185cf7e26a5/satelliteLib-b0f13d7a13ebe8b0b1b00a9f0730a084926e292f.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1581422282000" type="text/javascript"></script> <![endif]--> </head> <body class=" yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div id="js-cookie-message" class="cookie-message cookie-message--hidden system-message-container"> <div class="container"> <a href="#" class="fa fa-times js-cookie-close pull-right" aria-label="Close cookies message"></a> <div class="system-message-wrapper container"> <i class="fa fa-exclamation-triangle" aria-hidden="true"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/N7XGCZUQPW4C675JNSTYTLUDN7XB/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a href="#" class="btn secondary js-cookie-close js-cookie-accept">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/"> <span class="brand-name">The Cochrane Library</span> <img class="brand-logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_logo.png" alt="Cochrane Library logo" title="Cochrane Library" /> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="owel__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011599.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011599.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a href="/en/browse-by-topic" class="btn secondary">Browse</a>
<a href="/en/advanced-search" class="btn primary advanced-search-button">Advanced search</a>
</div>
</div>
<a href="#" class="toggle-menu-switch"><i class="fa fa-bars" aria-hidden="true"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<p class="auxiliary-menu-item access">Access provided by: <strong>Tsinghua University</strong></p>
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="bvrs__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="language-selector-modal-content" style="display: none;" data-modal-title="Language selection" data-size="large"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div> <a href="/en/cdsr/doi/10.1002/14651858.CD011599.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD011599.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <button class="btn primary btn-cancel" type="button">Cancel</button> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011599.pub2%2Freferences" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
</a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
<div class="access-provider-mobile">
<p class="access">Access provided by: <strong>Tsinghua University</strong></p>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
 <nav class="main container">
<ul>
<li class=" nav-root-item parent">
<a href="#">Cochrane Reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_14" role="presentation">
<a aria-labelledby="layout_14" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews" role="menuitem">
Search Reviews (CDSR)
</a>
</li>
<li class=" child-nav-item" id="layout_15" role="presentation">
<a aria-labelledby="layout_15" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews&#x2f;topics" role="menuitem">
Browse Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_18" role="presentation">
<a aria-labelledby="layout_18" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;table-of-contents" role="menuitem">
Issues
</a>
</li>
<li class=" child-nav-item" id="layout_17" role="presentation">
<a aria-labelledby="layout_17" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;editorials" role="menuitem">
Editorials
</a>
</li>
<li class=" child-nav-item" id="layout_19" role="presentation">
<a aria-labelledby="layout_19" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;special-collections" role="menuitem">
Special Collections
</a>
</li>
<li class=" child-nav-item" id="layout_20" role="presentation">
<a aria-labelledby="layout_20" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;supplements" role="menuitem">
Supplements
</a>
</li>
<li class=" child-nav-item" id="layout_13" role="presentation">
<a aria-labelledby="layout_13" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;about-cdsr" role="menuitem">
About the CDSR
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_22" role="presentation">
<a aria-labelledby="layout_22" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central" role="menuitem">
Search Trials (CENTRAL)
</a>
</li>
<li class=" child-nav-item" id="layout_114" role="presentation">
<a aria-labelledby="layout_114" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central&#x2f;about-central" role="menuitem">
About CENTRAL
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_29" role="presentation">
<a aria-labelledby="layout_29" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca" role="menuitem">
Browse Clinical Answers
</a>
</li>
<li class=" child-nav-item" id="layout_91" role="presentation">
<a aria-labelledby="layout_91" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca&#x2f;about" role="menuitem">
About Clinical Answers
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_116" role="presentation">
<a aria-labelledby="layout_116" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-library" role="menuitem">
About the Cochrane Library
</a>
</li>
<li class=" child-nav-item" id="layout_34" role="presentation">
<a aria-labelledby="layout_34" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochrane&#x2e;org&#x2f;about-us" role="menuitem">
About Cochrane
</a>
</li>
<li class=" child-nav-item" id="layout_121" role="presentation">
<a aria-labelledby="layout_121" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-reviews" role="menuitem">
About Cochrane Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_92" role="presentation">
<a aria-labelledby="layout_92" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;author-information" role="menuitem">
Information for authors
</a>
</li>
<li class=" child-nav-item" id="layout_188" role="presentation">
<a aria-labelledby="layout_188" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;releases" role="menuitem">
What&#039;s new
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_177" role="presentation">
<a aria-labelledby="layout_177" href="https&#x3a;&#x2f;&#x2f;www&#x2e;wiley&#x2e;com&#x2f;network&#x2f;cochranelibrarytraining" role="menuitem">
Cochrane Library Training
</a>
</li>
<li class=" child-nav-item" id="layout_44" role="presentation">
<a aria-labelledby="layout_44" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;access" role="menuitem">
Access options
</a>
</li>
<li class=" child-nav-item" id="layout_150" role="presentation">
<a aria-labelledby="layout_150" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;permissions" role="menuitem">
Permissions and reprints
</a>
</li>
<li class=" child-nav-item" id="layout_93" role="presentation">
<a aria-labelledby="layout_93" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;media" role="menuitem">
Media information
</a>
</li>
<li class=" child-nav-item" id="layout_97" role="presentation">
<a aria-labelledby="layout_97" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;contact-us" role="menuitem">
Contact us
</a>
</li>
<li class=" child-nav-item" id="layout_125" role="presentation">
<a aria-labelledby="layout_125" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;terms-and-conditions" role="menuitem">
Terms and conditions
</a>
</li>
<li class=" child-nav-item" id="layout_176" role="presentation">
<a aria-labelledby="layout_176" href="https&#x3a;&#x2f;&#x2f;hub&#x2e;wiley&#x2e;com&#x2f;docs&#x2f;cochrane-library&#x2f;cochrane-library-known-issues-DOC-16221&#x3f;referrer&#x3d;cochrane" role="menuitem">
Known issues
</a>
</li>
</ul>
</li>
<li class="about-link"><a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img id="etlj__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <section class="content-language-banner system-message-container" data-content-language="en" data-portal-language="en" style="display: none"> <div class="container"> <a href="#0" class="fa fa-times content-language-banner-close pull-right" aria-label="Close"></a> <i class="fa fa-globe" aria-hidden="true"></i> <div class="system-message-title">Content Language Selection</div> <div class="system-message-description">Your language preference is set to <strong class="language">English</strong>. Where translations are available, article sections will display in this language. Return to <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=reset-content-language&p_p_cacheability=cacheLevelPage" class="language secondary">English</a>.</div> </div> </section> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div id="content" class="">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="rjus__column1__0" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools"> <li class="cdsr-nav-link pulldown-menu readcube-menu closed"> <a href="#0" class="pulldown-menu-trigger"> <i class="icon fa fa-file-pdf-o"></i>View PDF <i aria-hidden="true" class="fa fa-caret-up"></i> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/pdf/full/en" class="download media pdf-link-full pdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/epdf/full/en" class="download media pdf-link-full readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/pdf/standard/en" class="download media pdf-link-standard pdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/epdf/standard/en" class="download media pdf-link-standard readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/pdf/abstract/en" class="download media pdf-link-abstract pdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/epdf/abstract/en" class="download media pdf-link-abstract readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="cdsr-nav-link cite-article-link" data-article-id="CD011599.PUB2" data-modal-title="Cite this Review"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/#"> <i class="icon fa fa-share"></i>Cite this Review </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-english-only-message="Please note, that requesting permissions is available in English only. Apologies for any inconvenience." href="/cdsr/doi/10.1002/14651858.CD011599.pub2/#" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false"> <span class="request-permissions-icon"></span> Request Permissions </a> </li> <li class="cdsr-nav-link comment-on-review"> <a id="comment-on-review" class="js-old-version-modal-trigger" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/comment" data-new-version="" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience."> <i class="icon fa fa-comment"></i>Comment on Review </a> </li> <li class="cdsr-nav-link comment-on"> <span>Read comments on this Review(0)</span> </li> </ul> <ul class="share clearfix"> <li class="cdsr-nav-link print-cdsr-link" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011599.pub2/print" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Data and analysis&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;}]}]"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/#"> <i class="icon fa fa-print"></i>Print </a> </li> <li class="cdsr-nav-link share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011599.pub2/full"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/#"> <i class="icon fa fa-share-alt"></i>Share </a> </li> <li class="cdsr-nav-link"> <a href="/c/portal/login" class="article-not-followed cochrane-link signin"> <span class="article-follow-display"><i class="icon fa fa-plus"></i>Follow</span> </a> </li> </ul> <ul id="linked-articles" data-type="cdsr" class="linked-content tools clearfix linked-content-trigger"> <li> <a href="#0"> <span class="linked-to-this"> Linked to this Review <span class="linked-content-count"></span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> </li> </ul> <ul class="linked-content-dropdown"> <li data-type="cca" class="linked-cca"> <p>Cochrane Clinical Answers</p> </li> <li data-type="editorial" class="linked-editorials"> <p>Editorials</p> </li> <li data-type="podcast" class="linked-podcasts"> <p>Podcasts</p> </li> <li data-type="sc" class="linked-sc"> <p>Special Collections</p> </li> </ul> <ul class="nav-long-form"> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-sec1-0006"> Discussion </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/appendices#CD011599-sec1-0012"> Appendices </a> </li> </ul> <ul> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information"> Information </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information#authors"> Authors </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information#history"> History </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/information#keywords"> Keywords </a> </li> </ul> <ul> <li class="cdsr-nav-link bold-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/#"> <i class="icon fa fa-globe"></i>Translation notes </a> </li> </ul> <ul> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references"> References </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#dataAndAnalyses"> Data and analyses </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/#"> <i class="icon fa fa-line-chart"></i>Figures and tables </a> </li> <li class="cdsr-nav-link download-stats-data-link " data-download-href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/table_n/CD011599StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/table_n/CD011599StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <i class="icon fa fa-download"></i>Download statistical data </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i>Related content <span class="note podcast-indicator">Podcast available</span> </a> </li> </ul> </nav> </div> <article class="information" data-article-id="CD011599.PUB2"> <header> <h1 class="publication-title"><h1 lang="en" class="publication-title">Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema </h1></h1> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div><h2 class="title section-collapse-title"> References <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <section class="references bibliographies" id="references"> <section> <div class="section-header" id="CD011599-bbs1-0001"> <h3 class="title">References to studies included in this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD011599-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0003">ongoing studies</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0004">additional references</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0005">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_includedStudies" id="CD011599-bbs2-0001"> <div class="reference-title-banner"> <h4 class="title">DRCRnet U 2018 {published data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0001"> <div class="citation-journal">Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, et al. <span class="citation-title">Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial</span>. <span class="citation"> JAMA Ophthalmology </span><span class="pubYear">2018</span>;<span class="volume">136</span>(1):29‐38. <a class="crsref citation-link central-link" data-crsref="7953589" href="" ref="info:x-wiley/crsRef/7953589" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/29127949" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+adding+dexamethasone+to+continued+ranibizumab+treatment+in+patients+with+persistent+diabetic+macular+edema:+a+DRCR+network+phase+2+randomized+clinical+trial+&author=RK+Maturi&author=AR+Glassman&author=D+Liu&author=RW+Beck&author=AR+Bhavsar&author=NM+Bressler&publication_year=2018&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011599-bib-0002"> <div class="citation-other">NCT01945866. <span class="citation-title">Phase II combination steroid and anti‐VEGF for persistent DME</span> [Short‐term evaluation of combination corticosteroid+anti‐VEGF treatment for persistent central‐involved diabetic macular edema following anti‐VEGF therapy]. clinicaltrials.gov/ct2/show/NCT01945866 (first received 19 September 2013). <a class="crsref citation-link central-link" data-crsref="7953590" href="" ref="info:x-wiley/crsRef/7953590" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011599-bbs2-0002"> <div class="reference-title-banner"> <h4 class="title">Lim 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0003"> <div class="citation-journal">Lim JW, Lee HK, Shin MC. <span class="citation-title">Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial</span>. <span class="citation"> Ophthalmologica </span><span class="pubYear">2012</span>;<span class="volume">227</span>(2):100‐6. <a class="crsref citation-link central-link" data-crsref="7953592" href="" ref="info:x-wiley/crsRef/7953592" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21997197" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+intravitreal+bevacizumab+alone+or+combined+with+triamcinolone+versus+triamcinolone+in+diabetic+macular+edema:+a+randomized+clinical+trial+&author=JW+Lim&author=HK+Lee&author=MC+Shin&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011599-bbs2-0003"> <div class="reference-title-banner"> <h4 class="title">Maturi 2015 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0004"> <div class="citation-journal">Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW. <span class="citation-title">A 12‐month, single‐masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti‐VEGF Injections to assess the efficacy of the dexamethasone‐delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy</span>. <span class="citation"> Retina </span><span class="pubYear">2015</span>;<span class="volume">35</span>(8):1604‐14. <a class="crsref citation-link central-link" data-crsref="7953594" href="" ref="info:x-wiley/crsRef/7953594" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25829346" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+12%E2%80%90month,+single%E2%80%90masked,+randomized+controlled+study+of+eyes+with+persistent+diabetic+macular+edema+after+multiple+anti%E2%80%90VEGF+Injections+to+assess+the+efficacy+of+the+dexamethasone%E2%80%90delayed+delivery+system+as+an+adjunct+to+bevacizumab+compared+with+continued+bevacizumab+monotherapy+&author=RK+Maturi&author=L+Bleau&author=J+Saunders&author=M+Mubasher&author=MW+Stewart&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011599-bbs2-0004"> <div class="reference-title-banner"> <h4 class="title">Neto 2017 {published data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0005"> <div class="citation-other">NCT00737971. <span class="citation-title">Efficacy study of triamcinolone and bevacizumab intravitreal for treatment of diabetic macular edema (ATEMD)</span> [Multicenter, randomized clinical trial to assess the effectiveness of intravitreal Injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT00737971 (first received 20 August 2008). <a class="crsref citation-link central-link" data-crsref="7953596" href="" ref="info:x-wiley/crsRef/7953596" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD011599-bib-0006"> <div class="citation-journal">Neto HO, Regatieri CV, Nobrega MJ, Muccioli C, Casella AM, Andrade RE, et al. <span class="citation-title">Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema</span>. <span class="citation"> Ophthalmic Surgery, Lasers and Imaging Retina </span><span class="pubYear">2017</span>;<span class="volume">48</span>(9):734‐40. <a class="crsref citation-link central-link" data-crsref="7953597" href="" ref="info:x-wiley/crsRef/7953597" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Multicenter,+randomized+clinical+trial+to+assess+the+effectiveness+of+intravitreal+injections+of+bevacizumab,+triamcinolone,+or+their+combination+in+the+treatment+of+diabetic+macular+edema+&author=HO+Neto&author=CV+Regatieri&author=MJ+Nobrega&author=C+Muccioli&author=AM+Casella&author=RE+Andrade&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011599-bbs2-0005"> <div class="reference-title-banner"> <h4 class="title">Riazi‐Esfahani 2017 {published data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0007"> <div class="citation-journal">Riazi‐Esfahani M, Riazi‐Esfahani H, Ahmadraji A, Karkhaneh R, Mahmoudi A, Roohipoor R, et al. <span class="citation-title">Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial</span>. <span class="citation"> International Ophthalmology </span><span class="pubYear">2017</span>;<span class="volume">37</span>:1‐14. <a class="crsref citation-link central-link" data-crsref="7953599" href="" ref="info:x-wiley/crsRef/7953599" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26968412" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+alone+or+combined+with+1+mg+triamcinolone+in+diabetic+macular+edema:+a+randomized+clinical+trial+&author=M+Riazi%E2%80%90Esfahani&author=H+Riazi%E2%80%90Esfahani&author=A+Ahmadraji&author=R+Karkhaneh&author=A+Mahmoudi&author=R+Roohipoor&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011599-bbs2-0006"> <div class="reference-title-banner"> <h4 class="title">Shoeibi 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0008"> <div class="citation-journal">Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, et al. <span class="citation-title">Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial</span>. <span class="citation"> Graefe's Archive for Clinical and Experimental Ophthalmology </span><span class="pubYear">2008</span>;<span class="volume">246</span>(4):483‐9. <a class="crsref citation-link central-link" data-crsref="7953601" href="" ref="info:x-wiley/crsRef/7953601" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17917738" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+with+or+without+triamcinolone+for+refractory+diabetic+macular+edema;+a+placebo%E2%80%90controlled,+randomized+clinical+trial+&author=H+Ahmadieh&author=A+Ramezani&author=N+Shoeibi&author=B+Bijanzadeh&author=A+Tabatabaei&author=M+Azarmina&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011599-bib-0009"> <div class="citation-journal">Shoeibi N, Ahmadieh H, Entezari M, Yaseri M. <span class="citation-title">Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long‐term results of a clinical trial</span>. <span class="citation"> Journal of Ophthalmic and Vision Research </span><span class="pubYear">2013</span>;<span class="volume">8</span>(2):99‐106. <a class="crsref citation-link central-link" data-crsref="7953602" href="" ref="info:x-wiley/crsRef/7953602" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23943683" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+with+or+without+triamcinolone+for+refractory+diabetic+macular+edema:+long%E2%80%90term+results+of+a+clinical+trial+&author=N+Shoeibi&author=H+Ahmadieh&author=M+Entezari&author=M+Yaseri&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011599-bbs2-0007"> <div class="reference-title-banner"> <h4 class="title">Soheilian 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0010"> <div class="citation-journal">Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA. <span class="citation-title">Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema</span>. <span class="citation"> Retina </span><span class="pubYear">2012</span>;<span class="volume">32</span>(2):314‐21. <a class="crsref citation-link central-link" data-crsref="7953604" href="" ref="info:x-wiley/crsRef/7953604" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22234244" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Two%E2%80%90year+results+of+a+randomized+trial+of+intravitreal+bevacizumab+alone+or+combined+with+triamcinolone+versus+laser+in+diabetic+macular+edema+&author=M+Soheilian&author=KH+Garfami&author=A+Ramezani&author=M+Yaseri&author=GA+Peyman&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011599-bib-0011"> <div class="citation-journal">Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, et al. <span class="citation-title">Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2009</span>;<span class="volume">116</span>(6):1142‐50. <a class="crsref citation-link central-link" data-crsref="7953605" href="" ref="info:x-wiley/crsRef/7953605" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19376585" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Randomized+trial+of+intravitreal+bevacizumab+alone+or+combined+with+triamcinolone+versus+macular+photocoagulation+in+diabetic+macular+edema+&author=M+Soheilian&author=A+Ramezani&author=A+Obudi&author=B+Bijanzadeh&author=M+Salehipour&author=M+Yaseri&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD011599-bib-0012"> <div class="citation-journal">Yaseri M, Zeraati H, Mohammad K, Soheilian M, Ramezani A, Eslani M, et al. <span class="citation-title">Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial</span>. <span class="citation"> Journal of Ophthalmic and Vision Research </span><span class="pubYear">2014</span>;<span class="volume">9</span>(4):453‐60. <a class="crsref citation-link central-link" data-crsref="7953606" href="" ref="info:x-wiley/crsRef/7953606" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25709771" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+injection+alone+or+combined+with+triamcinolone+versus+macular+photocoagulation+in+bilateral+diabetic+macular+edema;+application+of+bivariate+generalized+linear+mixed+model+with+asymmetric+random+effects+in+a+subgroup+of+a+clinical+trial+&author=M+Yaseri&author=H+Zeraati&author=K+Mohammad&author=M+Soheilian&author=A+Ramezani&author=M+Eslani&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD011599-bbs2-0008"> <div class="reference-title-banner"> <h4 class="title">Synek 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0013"> <div class="citation-journal">Synek S, Vesely P. <span class="citation-title">Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema</span>. <span class="citation"> Collegium Antropologicum </span><span class="pubYear">2011</span>;<span class="volume">35</span>(3):841‐5. <a class="crsref citation-link central-link" data-crsref="7953608" href="" ref="info:x-wiley/crsRef/7953608" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22053565" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+Bevacizumab+with+or+without+triamcinolone+for+refractory+diabetic+macular+oedema+&author=S+Synek&author=P+Vesely&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD011599-bbs1-0002"> <h3 class="title">References to studies excluded from this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD011599-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0003">ongoing studies</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0004">additional references</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0005">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011599-bbs2-0009"> <div class="reference-title-banner"> <h4 class="title">Faghihi 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0014"> <div class="citation-journal">Faghihi H, Roohipoor R, Mohammadi SF, Hojat‐Jalali K, Mirshahi A, Lashay A, et al. <span class="citation-title">Intravitreal bevacizumab versus combined bevacizumab‐triamcinolone versus macular laser photocoagulation in diabetic macular edema</span>. <span class="citation"> European Journal of Ophthalmology </span><span class="pubYear">2008</span>;<span class="volume">18</span>(6):941‐8. <a class="crsref citation-link central-link" data-crsref="7953610" href="" ref="info:x-wiley/crsRef/7953610" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18988166" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+versus+combined+bevacizumab%E2%80%90triamcinolone+versus+macular+laser+photocoagulation+in+diabetic+macular+edema+&author=H+Faghihi&author=R+Roohipoor&author=SF+Mohammadi&author=K+Hojat%E2%80%90Jalali&author=A+Mirshahi&author=A+Lashay&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011599-bbs2-0010"> <div class="reference-title-banner"> <h4 class="title">Sheth 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0015"> <div class="citation-journal">Sheth S, Rush R, Natarajan S, Gillies M. <span class="citation-title">Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema</span>. <span class="citation"> Clinical and Experimental Ophthalmology </span><span class="pubYear">2011</span>;<span class="volume">39</span>(7):673‐81. <a class="crsref citation-link central-link" data-crsref="7953612" href="" ref="info:x-wiley/crsRef/7953612" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22452685" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+triamcinolone+acetonide+versus+combined+intravitreal+bevacizumab+and+dexamethasone+in+diffuse+diabetic+macular+oedema+&author=S+Sheth&author=R+Rush&author=S+Natarajan&author=M+Gillies&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011599-bbs2-0011"> <div class="reference-title-banner"> <h4 class="title">Soheilian 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0016"> <div class="citation-journal">Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, et al. <span class="citation-title">Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema</span>. <span class="citation"> Retina </span><span class="pubYear">2007</span>;<span class="volume">27</span>(9):1187‐95. <a class="crsref citation-link central-link" data-crsref="7953614" href="" ref="info:x-wiley/crsRef/7953614" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18046223" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+(avastin)+injection+alone+or+combined+with+triamcinolone+versus+macular+photocoagulation+as+primary+treatment+of+diabetic+macular+edema+&author=M+Soheilian&author=A+Ramezani&author=B+Bijanzadeh&author=M+Yaseri&author=H+Ahmadieh&author=MH+Dehghan&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011599-bbs2-0012"> <div class="reference-title-banner"> <h4 class="title">Wang 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0017"> <div class="citation-journal">Wang YS, Li X, Wang HY, Zhang ZF, Li MH, Su XN. <span class="citation-title">Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema</span>. <span class="citation"> Chinese Medical Journal </span><span class="pubYear">2011</span>;<span class="volume">124</span>(3):352‐8. <a class="crsref citation-link central-link" data-crsref="7953616" href="" ref="info:x-wiley/crsRef/7953616" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21362332" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+combined+with/without+triamcinolone+acetonide+in+single+injection+for+treatment+of+diabetic+macular+edema+&author=YS+Wang&author=X+Li&author=HY+Wang&author=ZF+Zhang&author=MH+Li&author=XN+Su&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD011599-bbs2-0013"> <div class="reference-title-banner"> <h4 class="title">Yu 2018 {published data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0018"> <div class="citation-journal">Yu S Y, Nam D H, Lee D Y. <span class="citation-title">Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema</span>. <span class="citation"> Graefes Arch Clin Exp Ophthalmol </span><span class="pubYear">2018</span>;<span class="volume">256</span>:39‐47. <a class="crsref citation-link central-link" data-crsref="7953618" href="" ref="info:x-wiley/crsRef/7953618" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/29030692" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Changes+in+aqueous+concentrations+of+various+cytokines+after+intravitreal+bevacizumab+and+subtenon+triamcinolone+injection+for+diabetic+macular+edema+&author=SY+Yu&author=DH+Nam&author=DY+Lee&publication_year=2018&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD011599-bbs1-0003"> <h3 class="title">References to ongoing studies</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD011599-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0004">additional references</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0005">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD011599-bbs2-0014"> <div class="reference-title-banner"> <h4 class="title">NCT03126786 {published data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0019"> <div class="citation-other">NCT03126786. <span class="citation-title">Suprachoroidal CLS‐TA with intravitreal aflibercept versus aflibercept alone in subject with diabetic macular edema (TYBEE)</span>. clinicaltrials.gov/show/NCT03126786 (first posted 24 April 2017). <a class="crsref citation-link central-link" data-crsref="7953620" href="" ref="info:x-wiley/crsRef/7953620" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD011599-bbs2-0015"> <div class="reference-title-banner"> <h4 class="title">UMIN000021630 {unpublished data only} </h4> </div> <div class="bibliography-section" id="CD011599-bib-0020"> <div class="citation-other">UMIN000021630. <span class="citation-title">Anti‐VEGF and steroid combination therapy for diabetic macular edema</span>. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000021630 (date of registration 27 March 2016). <a class="crsref citation-link central-link" data-crsref="7953622" href="" ref="info:x-wiley/crsRef/7953622" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD011599-bbs1-0004"> <h3 class="title">Additional references</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD011599-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0003">ongoing studies</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0005">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0016"> <div class="reference-title-banner"> <h4 class="title">Ahmadieh 2008</h4> </div> <div class="bibliography-section" id="CD011599-bib-0021"> <div class="citation-journal">Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, et al. <span class="citation-title">Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial</span>. <span class="citation"> Graefe's Archive for Clinical and Experimental Ophthalmology </span><span class="pubYear">2008</span>;<span class="volume">246</span>(4):483‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17917738" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+with+or+without+triamcinolone+for+refractory+diabetic+macular+edema;+a+placebo%E2%80%90controlled,+randomized+clinical+trial+&author=H+Ahmadieh&author=A+Ramezani&author=N+Shoeibi&author=B+Bijanzadeh&author=A+Tabatabaei&author=M+Azarmina&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0017"> <div class="reference-title-banner"> <h4 class="title">Aiello 2005</h4> </div> <div class="bibliography-section" id="CD011599-bib-0022"> <div class="citation-journal">Aiello LP. <span class="citation-title">Angiogenic pathways in diabetic retinopathy</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2005</span>;<span class="volume">353</span>(8):839‐41. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16120866" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Angiogenic+pathways+in+diabetic+retinopathy&author=LP+Aiello&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0018"> <div class="reference-title-banner"> <h4 class="title">Amoaku 2015</h4> </div> <div class="bibliography-section" id="CD011599-bib-0023"> <div class="citation-journal">Amoaku WM, Saker S, Stewart EA. <span class="citation-title">A review of therapies for diabetic macular oedema and rationale for combination therapy</span>. <span class="citation"> Eye </span><span class="pubYear">2015</span>;<span class="volume">29</span>(9):1115‐30. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26113500" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+review+of+therapies+for+diabetic+macular+oedema+and+rationale+for+combination+therapy&author=WM+Amoaku&author=S+Saker&author=EA+Stewart&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0019"> <div class="reference-title-banner"> <h4 class="title">Antonetti 2012</h4> </div> <div class="bibliography-section" id="CD011599-bib-0024"> <div class="citation-journal">Antonetti DA, Klein R, Gardner TW. <span class="citation-title">Diabetic retinopathy</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2012</span>;<span class="volume">366</span>(13):1227‐39. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22455417" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+retinopathy&author=DA+Antonetti&author=R+Klein&author=TW+Gardner&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0020"> <div class="reference-title-banner"> <h4 class="title">APTC 1994</h4> </div> <div class="bibliography-section" id="CD011599-bib-0025"> <div class="citation-journal">Antiplatelet Trialists' Collaboration. <span class="citation-title">Collaborative overview of randomised trials of antiplatelet therapy‐I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients</span>. <span class="citation"> BMJ </span><span class="pubYear">1994</span>;<span class="volume">308</span>(6921):81‐106. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8298418" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0021"> <div class="reference-title-banner"> <h4 class="title">Bailey 1976</h4> </div> <div class="bibliography-section" id="CD011599-bib-0026"> <div class="citation-journal">Bailey IL, Lovie JE. <span class="citation-title">New design principles for visual acuity letter charts</span>. <span class="citation"> American Journal of Optometry and Physiological Optics </span><span class="pubYear">1976</span>;<span class="volume">53</span>(11):740‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/998716" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=New+design+principles+for+visual+acuity+letter+charts&author=IL+Bailey&author=JE+Lovie&publication_year=1976&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0022"> <div class="reference-title-banner"> <h4 class="title">BEVORDEX 2014</h4> </div> <div class="bibliography-section" id="CD011599-bib-0027"> <div class="citation-journal">Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. <span class="citation-title">A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2014</span>;<span class="volume">121</span>(12):2473‐81. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25155371" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+randomized+clinical+trial+of+intravitreal+bevacizumab+versus+intravitreal+dexamethasone+for+diabetic+macular+edema:+the+BEVORDEX+study+&author=MC+Gillies&author=LL+Lim&author=A+Campain&author=GJ+Quin&author=W+Salem&author=J+Li&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0023"> <div class="reference-title-banner"> <h4 class="title">BEVORDEX 2016</h4> </div> <div class="bibliography-section" id="CD011599-bib-0028"> <div class="citation-journal">Fraser‐Bell S, Lim LL, Campain A, Mehta H, Aroney C, Bryant J, et al. <span class="citation-title">Bevacizumab or dexamethasone implants for DME: 2‐year results (The BEVORDEX Study)</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2016</span>;<span class="volume">123</span>(6):1399‐01. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26783096" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Bevacizumab+or+dexamethasone+implants+for+DME:+2%E2%80%90year+results+(The+BEVORDEX+Study)&author=S+Fraser%E2%80%90Bell&author=LL+Lim&author=A+Campain&author=H+Mehta&author=C+Aroney&author=J+Bryant&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0024"> <div class="reference-title-banner"> <h4 class="title">Boyer 2009</h4> </div> <div class="bibliography-section" id="CD011599-bib-0029"> <div class="citation-journal">Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. <span class="citation-title">A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age‐related macular degeneration</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2009</span>;<span class="volume">116</span>(9):1731‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19643495" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+phase+IIIb+study+to+evaluate+the+safety+of+ranibizumab+in+subjects+with+neovascular+age%E2%80%90related+macular+degeneration+&author=DS+Boyer&author=JS+Heier&author=DM+Brown&author=SF+Francom&author=T+Ianchulev&author=RG+Rubio&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0025"> <div class="reference-title-banner"> <h4 class="title">Boyer 2011</h4> </div> <div class="bibliography-section" id="CD011599-bib-0030"> <div class="citation-journal">Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, et al. <span class="citation-title">Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients</span>. <span class="citation"> Retina </span><span class="pubYear">2011</span>;<span class="volume">31</span>(5):915‐23. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21487341" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dexamethasone+intravitreal+implant+for+treatment+of+diabetic+macular+edema+in+vitrectomized+patients+&author=DS+Boyer&author=D+Faber&author=S+Gupta&author=SS+Patel&author=H+Tabandeh&author=XY+Li&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0026"> <div class="reference-title-banner"> <h4 class="title">Bunce 2008</h4> </div> <div class="bibliography-section" id="CD011599-bib-0031"> <div class="citation-journal">Bunce C, Wormald R. <span class="citation-title">Causes of blind certifications in England and Wales: April 1999‐March 2000</span>. <span class="citation"> Eye </span><span class="pubYear">2008</span>;<span class="volume">22</span>(7):905‐11. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17332762" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Causes+of+blind+certifications+in+England+and+Wales:+April+1999%E2%80%90March+2000&author=C+Bunce&author=R+Wormald&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0027"> <div class="reference-title-banner"> <h4 class="title">Campochiaro 2012</h4> </div> <div class="bibliography-section" id="CD011599-bib-0032"> <div class="citation-journal">Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz‐Moreno J, et al. <span class="citation-title">Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2012</span>;<span class="volume">119</span>(10):2125‐32. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22727177" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sustained+delivery+fluocinolone+acetonide+vitreous+inserts+provide+benefit+for+at+least+3+years+in+patients+with+diabetic+macular+edema+&author=PA+Campochiaro&author=DM+Brown&author=A+Pearson&author=S+Chen&author=D+Boyer&author=J+Ruiz%E2%80%90Moreno&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0028"> <div class="reference-title-banner"> <h4 class="title">Deeks 2011</h4> </div> <div class="bibliography-section" id="CD011599-bib-0033"> <div class="citation-other">Deeks JJ, Higgins JP, Altman DG editor(s). <span class="citation-title">Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</span>. Available from handbook.cochrane.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0029"> <div class="reference-title-banner"> <h4 class="title">ETDRS 1991</h4> </div> <div class="bibliography-section" id="CD011599-bib-0034"> <div class="citation-journal">Early Treatment Diabetic Retinopathy Study Research Group. <span class="citation-title">Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1991</span>;<span class="volume">98</span>(5 Suppl):807‐22. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2062514" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0030"> <div class="reference-title-banner"> <h4 class="title">Funatsu 2003</h4> </div> <div class="bibliography-section" id="CD011599-bib-0035"> <div class="citation-journal">Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. <span class="citation-title">Vitreous levels of interleukin‐6 and vascular endothelial growth factor are related to diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2003</span>;<span class="volume">110</span>(9):1690‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/13129863" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Vitreous+levels+of+interleukin%E2%80%906+and+vascular+endothelial+growth+factor+are+related+to+diabetic+macular+edema+&author=H+Funatsu&author=H+Yamashita&author=T+Ikeda&author=T+Mimura&author=S+Eguchi&author=S+Hori&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0031"> <div class="reference-title-banner"> <h4 class="title">Funatsu 2005</h4> </div> <div class="bibliography-section" id="CD011599-bib-0036"> <div class="citation-journal">Funatsu H, Yamashita H, Sakata K, Noma H, Mimura T, Suzuki M, et al. <span class="citation-title">Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2005</span>;<span class="volume">112</span>(5):806‐16. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15878060" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Vitreous+levels+of+vascular+endothelial+growth+factor+and+intercellular+adhesion+molecule+1+are+related+to+diabetic+macular+edema+&author=H+Funatsu&author=H+Yamashita&author=K+Sakata&author=H+Noma&author=T+Mimura&author=M+Suzuki&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0032"> <div class="reference-title-banner"> <h4 class="title">Gillies 2009</h4> </div> <div class="bibliography-section" id="CD011599-bib-0037"> <div class="citation-journal">Gillies MC, Simpson JM, Gaston C, Hunt G, Ali H, Zhu M, et al. <span class="citation-title">Five‐year results of a randomized trial with open‐label extension of triamcinolone acetonide for refractory diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2009</span>;<span class="volume">116</span>(11):2182–7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19796823" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Five%E2%80%90year+results+of+a+randomized+trial+with+open%E2%80%90label+extension+of+triamcinolone+acetonide+for+refractory+diabetic+macular+edema+&author=MC+Gillies&author=JM+Simpson&author=C+Gaston&author=G+Hunt&author=H+Ali&author=M+Zhu&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0033"> <div class="reference-title-banner"> <h4 class="title">Glanville 2006</h4> </div> <div class="bibliography-section" id="CD011599-bib-0038"> <div class="citation-journal">Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. <span class="citation-title">How to identify randomized controlled trials in MEDLINE: ten years on</span>. <span class="citation"> Journal of the Medical Library Association </span><span class="pubYear">2006</span>;<span class="volume">94</span>(2):130‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16636704" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=How+to+identify+randomized+controlled+trials+in+MEDLINE:+ten+years+on&author=JM+Glanville&author=C+Lefebvre&author=JN+Miles&author=J+Camosso%E2%80%90Stefinovic&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0034"> <div class="reference-title-banner"> <h4 class="title">Grover 2008</h4> </div> <div class="bibliography-section" id="CD011599-bib-0039"> <div class="citation-journal">Grover D, Li TJ, Chong CCW. <span class="citation-title">Intravitreal steroids for macular edema in diabetes</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2008</span>, Issue 1. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD005656.pub2" target="_blank"><span>10.1002/14651858.CD005656.pub2</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18254088" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+steroids+for+macular+edema+in+diabetes&author=D+Grover&author=TJ+Li&author=CCW+Chong&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0035"> <div class="reference-title-banner"> <h4 class="title">Higgins 2011</h4> </div> <div class="bibliography-section" id="CD011599-bib-0040"> <div class="citation-other">Higgins JP, Altman DG, Sterne JAC editor(s). <span class="citation-title">Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</span>. Available from handbook.cochrane.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0036"> <div class="reference-title-banner"> <h4 class="title">International Diabetes Federation 2011</h4> </div> <div class="bibliography-section" id="CD011599-bib-0041"> <div class="citation-book">International Diabetes Federation. <span class="citation">Diabetes Atlas</span>. 5th Edition. Brussels: International Diabetes Federation, <span class="pubYear">2011</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0037"> <div class="reference-title-banner"> <h4 class="title">Keech 2007</h4> </div> <div class="bibliography-section" id="CD011599-bib-0042"> <div class="citation-journal">Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. <span class="citation-title">Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2007</span>;<span class="volume">370</span>(9600):1687‐97. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17988728" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+fenofibrate+on+the+need+for+laser+treatment+for+diabetic+retinopathy+(FIELD+study):+a+randomised+controlled+trial+&author=AC+Keech&author=P+Mitchell&author=PA+Summanen&author=J+O'Day&author=TM+Davis&author=MS+Moffitt&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0038"> <div class="reference-title-banner"> <h4 class="title">Kiire 2013</h4> </div> <div class="bibliography-section" id="CD011599-bib-0043"> <div class="citation-journal">Kiire CA, Porta M, Chong V. <span class="citation-title">Medical management for the prevention and treatment of diabetic macular edema</span>. <span class="citation"> Survey of Ophthalmology </span><span class="pubYear">2013</span>;<span class="volume">58</span>(5):459‐65. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23969020" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Medical+management+for+the+prevention+and+treatment+of+diabetic+macular+edema&author=CA+Kiire&author=M+Porta&author=V+Chong&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0039"> <div class="reference-title-banner"> <h4 class="title">Liew 2008</h4> </div> <div class="bibliography-section" id="CD011599-bib-0044"> <div class="citation-journal">Liew G, Gillies MC, Wang JJ. <span class="citation-title">Fenofibrate and diabetic retinopathy</span>. <span class="citation"> Lancet </span><span class="pubYear">2008</span>;<span class="volume">371</span>(9614):721. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18313494" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Fenofibrate+and+diabetic+retinopathy&author=G+Liew&author=MC+Gillies&author=JJ+Wang&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0040"> <div class="reference-title-banner"> <h4 class="title">Mehta 2016</h4> </div> <div class="bibliography-section" id="CD011599-bib-0045"> <div class="citation-journal">Mehta H, Fraser‐Bell S, Yeung A, Campain A, Lim LL, Quin GJ, et al. <span class="citation-title">Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial</span>. <span class="citation"> British Journal of Ophthalmology </span><span class="pubYear">2016</span>;<span class="volume">100</span>(7):1000‐4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26537156" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+of+dexamethasone+versus+bevacizumab+on+regression+of+hard+exudates+in+diabetic+maculopathy:+data+from+the+BEVORDEX+randomised+clinical+trial+&author=H+Mehta&author=S+Fraser%E2%80%90Bell&author=A+Yeung&author=A+Campain&author=LL+Lim&author=GJ+Quin&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0041"> <div class="reference-title-banner"> <h4 class="title">Moss 1998</h4> </div> <div class="bibliography-section" id="CD011599-bib-0046"> <div class="citation-journal">Moss SE, Klein R, Klein BE. <span class="citation-title">The 14‐year incidence of visual loss in a diabetic population</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1998</span>;<span class="volume">105</span>(6):998‐1003. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9627648" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+14%E2%80%90year+incidence+of+visual+loss+in+a+diabetic+population&author=SE+Moss&author=R+Klein&author=BE+Klein&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0042"> <div class="reference-title-banner"> <h4 class="title">Review Manager 2014 [Computer program]</h4> </div> <div class="bibliography-section" id="CD011599-bib-0047"> <div class="citation-other">Nordic Cochrane Centre, The Cochrane Collaboration. <span class="citation-title">Review Manager 5 (RevMan 5)</span>. Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, <span class="pubYear">2014</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0043"> <div class="reference-title-banner"> <h4 class="title">Scheen 2010</h4> </div> <div class="bibliography-section" id="CD011599-bib-0048"> <div class="citation-journal">Scheen AJ, Gaal LF. <span class="citation-title">Accord‐lipid and accord‐eye: towards a new positioning of fenofibrate in the management of type 2 diabetes</span>. <span class="citation"> Revue Medicale de Liege </span><span class="pubYear">2010</span>;<span class="volume">65</span>(9):533‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21086587" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Accord%E2%80%90lipid+and+accord%E2%80%90eye:+towards+a+new+positioning+of+fenofibrate+in+the+management+of+type+2+diabetes+&author=AJ+Scheen&author=LF+Gaal&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0044"> <div class="reference-title-banner"> <h4 class="title">Schünemann 2011a</h4> </div> <div class="bibliography-section" id="CD011599-bib-0049"> <div class="citation-other">Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. <span class="citation-title">Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</span>. Available from handbook.cochrane.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0045"> <div class="reference-title-banner"> <h4 class="title">Schünemann 2011b</h4> </div> <div class="bibliography-section" id="CD011599-bib-0050"> <div class="citation-other">Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. <span class="citation-title">Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</span>. Available from handbook.cochrane.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0046"> <div class="reference-title-banner"> <h4 class="title">Simunovic 2014</h4> </div> <div class="bibliography-section" id="CD011599-bib-0051"> <div class="citation-journal">Simunovic MP, Hunyor AP, Ho IV. <span class="citation-title">Vitrectomy for diabetic macular edema: a systematic review and meta‐analysis</span>. <span class="citation"> Canadian Journal of Ophthalmology </span><span class="pubYear">2014</span>;<span class="volume">49</span>(2):188‐95. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24767227" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Vitrectomy+for+diabetic+macular+edema:+a+systematic+review+and+meta%E2%80%90analysis&author=MP+Simunovic&author=AP+Hunyor&author=IV+Ho&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0047"> <div class="reference-title-banner"> <h4 class="title">Soheilian 2009</h4> </div> <div class="bibliography-section" id="CD011599-bib-0052"> <div class="citation-journal">Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, et al. <span class="citation-title">Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2009</span>;<span class="volume">116</span>(6):1142‐50. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19376585" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Randomized+trial+of+intravitreal+bevacizumab+alone+or+combined+with+triamcinolone+versus+macular+photocoagulation+in+diabetic+macular+edema+&author=M+Soheilian&author=A+Ramezani&author=A+Obudi&author=B+Bijanzadeh&author=M+Salehipour&author=M+Yaseri&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0048"> <div class="reference-title-banner"> <h4 class="title">Virgili 2014</h4> </div> <div class="bibliography-section" id="CD011599-bib-0053"> <div class="citation-journal">Virgili G, Parravano M, Menchini F, Evans JR. <span class="citation-title">Anti‐vascular endothelial growth factor for diabetic macular oedema</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2014</span>, Issue 10. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD007419.pub4" target="_blank"><span>10.1002/14651858.CD007419.pub4</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Anti%E2%80%90vascular+endothelial+growth+factor+for+diabetic+macular+oedema&author=G+Virgili&author=M+Parravano&author=F+Menchini&author=JR+Evans&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0049"> <div class="reference-title-banner"> <h4 class="title">Virgili 2017</h4> </div> <div class="bibliography-section" id="CD011599-bib-0054"> <div class="citation-journal">Virgili G, Parravano M, Menchini F, Evans JR, Gordon I, Lucenteforte E. <span class="citation-title">Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2017</span>, Issue 6. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD007419.pub5" target="_blank"><span>10.1002/14651858.CD007419.pub5</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Anti%E2%80%90vascular+endothelial+growth+factor+for+diabetic+macular+oedema:+a+network+meta%E2%80%90analysis&author=G+Virgili&author=M+Parravano&author=F+Menchini&author=JR+Evans&author=I+Gordon&author=E+Lucenteforte&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0050"> <div class="reference-title-banner"> <h4 class="title">Wang 2008</h4> </div> <div class="bibliography-section" id="CD011599-bib-0055"> <div class="citation-journal">Wang K, Wang Y, Gao L, Li X, Li M, Guo J. <span class="citation-title">Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin‐induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule‐1 expression</span>. <span class="citation"> Biological and Pharmaceutical Bulletin </span><span class="pubYear">2008</span>;<span class="volume">31</span>(8):1541‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18670086" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dexamethasone+inhibits+leukocyte+accumulation+and+vascular+permeability+in+retina+of+streptozotocin%E2%80%90induced+diabetic+rats+via+reducing+vascular+endothelial+growth+factor+and+intercellular+adhesion+molecule%E2%80%901+expression+&author=K+Wang&author=Y+Wang&author=L+Gao&author=X+Li&author=M+Li&author=J+Guo&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0051"> <div class="reference-title-banner"> <h4 class="title">Wickremasinghe 2017</h4> </div> <div class="bibliography-section" id="CD011599-bib-0056"> <div class="citation-journal">Wickremasinghe SS, Fraser‐Bell S, Alessandrello E, Mehta H, Gillies MC, Lim LL. <span class="citation-title">Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema</span>. <span class="citation"> British Journal of Ophthalmology </span><span class="pubYear">2017</span>;<span class="volume">101</span>(10):1329‐33. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28228411" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Retinal+vascular+calibre+changes+after+intravitreal+bevacizumab+or+dexamethasone+implant+treatment+for+diabetic+macular+oedema+&author=SS+Wickremasinghe&author=S+Fraser%E2%80%90Bell&author=E+Alessandrello&author=H+Mehta&author=MC+Gillies&author=LL+Lim&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0052"> <div class="reference-title-banner"> <h4 class="title">Wong 2008</h4> </div> <div class="bibliography-section" id="CD011599-bib-0057"> <div class="citation-journal">Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, et al. <span class="citation-title">Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease</span>. <span class="citation"> Retina </span><span class="pubYear">2008</span>;<span class="volume">28</span>(8):1151‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18685542" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Surveillance+for+potential+adverse+events+associated+with+the+use+of+intravitreal+bevacizumab+for+retinal+and+choroidal+vascular+disease+&author=LJ+Wong&author=RU+Desai&author=A+Jain&author=D+Feliciano&author=DM+Moshfeghi&author=SR+Sanislo&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0053"> <div class="reference-title-banner"> <h4 class="title">Yaseri 2014</h4> </div> <div class="bibliography-section" id="CD011599-bib-0058"> <div class="citation-journal">Yaseri M, Zeraati H, Mohammad K, Soheilian M, Ramezani A, Eslani M, et al. <span class="citation-title">Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial</span>. <span class="citation"> Journal of Ophthalmic and Vision Research </span><span class="pubYear">2014</span>;<span class="volume">9</span>(4):453‐60. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25709771" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+injection+alone+or+combined+with+triamcinolone+versus+macular+photocoagulation+in+bilateral+diabetic+macular+edema;+application+of+bivariate+generalized+linear+mixed+model+with+asymmetric+random+effects+in+a+subgroup+of+a+clinical+trial+&author=M+Yaseri&author=H+Zeraati&author=K+Mohammad&author=M+Soheilian&author=A+Ramezani&author=M+Eslani&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD011599-bbs2-0054"> <div class="reference-title-banner"> <h4 class="title">Yau 2012</h4> </div> <div class="bibliography-section" id="CD011599-bib-0059"> <div class="citation-journal">Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. <span class="citation-title">Global prevalence and major risk factors of diabetic retinopathy</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2012</span>;<span class="volume">35</span>(3):556‐64. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22301125" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Global+prevalence+and+major+risk+factors+of+diabetic+retinopathy&author=JW+Yau&author=SL+Rogers&author=R+Kawasaki&author=EL+Lamoureux&author=JW+Kowalski&author=T+Bek&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD011599-bbs1-0005"> <h3 class="title">References to other published versions of this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD011599-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0003">ongoing studies</a></li> <li><a class="jump-to" href="#CD011599-bbs1-0004">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_otherVersions" id="CD011599-bbs2-0055"> <div class="reference-title-banner"> <h4 class="title">Mehta 2015</h4> </div> <div class="bibliography-section" id="CD011599-bib-0060"> <div class="citation-journal">Mehta H, Fraser‐Bell S, Campain A, Gillies MC. <span class="citation-title">Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2015</span>, Issue 3. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD011599" target="_blank"><span>10.1002/14651858.CD011599</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26086765" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Anti%E2%80%90vascular+endothelial+growth+factor+combined+with+intravitreal+steroids+for+diabetic+macular+oedema+&author=H+Mehta&author=S+Fraser%E2%80%90Bell&author=A+Campain&author=MC+Gillies&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> </section> <section class="characteristicStudies" id="characteristicStudies"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title"> Characteristics of studies <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="characteristicIncludedStudiesContent" lang=""> <div class="section-header" id="CD011599-sec2-0029"> <h3 class="title">Characteristics of included studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD011599-sec2-0030" class="jump-to">excluded studies</a></li> <li><a href="#CD011599-sec2-0031" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">DRCRnet U 2018 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design</b>: parallel group RCT/within‐person study (40 clinical centres) </p> <p><b>Unit of randomisation</b>:people and eyes if both eyes eligible </p> <p><b>Number randomised</b>: </p> <p>116 people, 129 eyes</p> <p><b>Unit of analysis</b>: individual eyes </p> <p><b>Sample size</b>: For a sample size of 70 study eyes per group (increased to 75 to account for approximately 5% loss to follow‐up), a 2‐sided 95% CI for the difference in the 2 means of visual acuity change from randomisation to 24 week visit will extend 2.3 visual acuity letter score in either direction from the observed difference in means, assuming that the common standard deviation is a letter score of 7, not adjusting for correlation between eyes in participants with 2 study eyes. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country</b>: USA </p> <p><b>Mean age</b>: 65 years </p> <p><b>Sex</b>: 67 women; 62 men </p> <p><b>Underlying condition</b>: persistent DMO </p> <p><b>Inclusion criteria</b>: age ≥ 18 years; diagnosis of diabetes mellitus (type 1 or type 2); meets all of the following ocular criteria in at least the one eye: at least 3 injections of anti‐VEGF drug (ranibizumab, bevacizumab, or aflibercept) within the prior 20 weeks, visual acuity letter score in study eye ≤ 78 and ≥ 24 LogMAR letters (approximate Snellen equivalent 20/32 to 20/320), on clinical exam, definite retinal thickening due to DMO involving the centre of the macula, OCT CMT thickness greater than 300 μm before adjusting for sex and machine‐specific factors </p> <p><b>Exclusion criteria</b>: chronic kidney disease, renal transplant; unstable medical status including blood pressure, cardiovascular disease, and glycaemic control; participation in an investigational trial within 30 days of enrolment; systolic blood pressure &gt; 180 mmHg; acute cardiovascular event within 1 month prior to enrolment; systemic steroid, anti‐VEGF or pro‐VEGF treatment within prior 4 months; pregnant; macular oedema is considered to be due to a cause other than DMO; an ocular condition is present (other than DMO) that, in the opinion of the investigator, might affect macular oedema or alter visual acuity during the course of the study; substantial posterior capsule opacity; history of intravitreal anti‐VEGF drug within 21 days prior to enrolment; history of intravitreal or peribulbar corticosteroids within 3 months prior to enrolment; history of macular laser photocoagulation within 4 months prior to enrolment; laser therapy within 4 previous months; any history of vitrectomy. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: intravitreal ranibizumab (0.3 mg) and dexamethasone implant (0.7g) </p> <p><b>Comparator</b>:<b>i</b>ntravitreal ranibizumab (0.3 mg) and sham injection </p> <p>Dexamethasone: sustained dexamethasone drug delivery system. Retreatment: ranibizumab was administered if the visual acuity letter score was less than 84 (approximate Snellen equivalent of 20/25 or worse) or the OCT CST was at or above the pre‐defined cut‐points. At the 4‐week and 8‐week visits, only ranibizumab injections were permitted. At 12 weeks and continuing through 20 weeks, retreatment was according to allocation group. A maximum of 2 injections of either dexamethasone or sham treatment were given in each eye. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome measure</b>: </p> <p> <ul id="CD011599-lst1-0013"> <li> <p>mean change in visual acuity letter score</p> </li> </ul> </p> <p><b>Secondary</b> o<b>utcome measures</b>: </p> <p> <ul id="CD011599-lst1-0014"> <li> <p>percentage of eyes with at least 10 and at least 15 ETDRS letter gain (increase) or loss (decrease) in visual acuity. </p> </li> <li> <p>visual acuity area under the curve (AUC)</p> </li> <li> <p>mean change in OCT central macular thickness</p> </li> <li> <p>percentage of eyes with worsening or improvement of diabetic retinopathy on clinical exam </p> </li> </ul> </p> <p><b>Length of follow‐up</b>: 6 months (24 weeks) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial registration</b>: NCT01945866 </p> <p><b>Source of funding</b>: EY14231 (other grant/funding number: National Eye Institute), EY23207 (other grant/funding number: National Eye Institute), EY18817 (other grant/funding number: National Eye Institute) </p> <p><b>Declaration of interest:</b> Several of the authors report receiving consultancy fees from the manufacturer of the implant, for example, quote "Dr Maturi reported receiving consultancy fees, research grants, payment for manuscript preparation, and travel, accommodations, and<br> meeting expenses from Allergan, Inc" </p> <p><b>Date study conducted:</b> February 2014 to December 2016 </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "Randomization was performed on the study website (http://www.drcr.net) using a permuted‐block design." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "Randomization was performed on the study website (http://www.drcr.net) using a permuted‐block design." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "Study participants and the medical monitor, who reviewed all adverse events, were masked to treatment group assignments. Refractionists, visual acuity testers, and OCT technicians were masked at the 24‐week primary outcome visit. Investigators and study coordinators were not masked." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "Study participants and the medical monitor, who reviewed all adverse events, were masked to treatment group assignments. Refractionists, visual acuity testers, and OCT technicians were masked at the 24‐week primary outcome visit. Investigators and study coordinators were not masked." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High follow‐up (127/129, 98%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Almost all outcomes on clinical trials registry were reported. The exception "Percent of eyes with worsening or improvement of diabetic retinopathy on clinical exam [ Time Frame: 24 weeks after randomization ]" was not an outcome of this review. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Both eyes being eligible to allocation in a single individual poses the theoretical potential to influence outcomes in the fellow eye via systemic absorption. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Lim 2012 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design</b>: parallel group RCT </p> <p><b>Unit of randomisation</b>: participants were randomly allocated to treatment. For participants with both eyes eligible on entry, the allocated randomised treatment was applied to the right eye, whereas the left eye received the other treatment. </p> <p><b>Number randomised</b>: </p> <p>Total: 120 eyes, 110 participants, 10 people had both eyes enrolled</p> <p><b>Unit of analysis</b>: individual eyes </p> <p><b>Number analysed</b>: </p> <p>Total: 111 eyes</p> <p>There were 6 study eyes lost to follow‐up and 3 eyes declined to continue intervention</p> <p>Intervention arms: 36 eyes anti‐VEGF/steroid, 38 eyes anti‐VEGF, 37 eyes IVS</p> <p>There were 36 eyes per group required for an 80% power to detect a<br> significance level of 5% in a two‐sided test of the outcome measures. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country</b>: South Korea </p> <p><b>Mean age</b>: 60 years </p> <p><b>Sex</b>: 55 women; 50 men </p> <p><b>Underlying condition</b>: DMO </p> <p><b>Inclusion criteria</b>: eyes with clinically significant DMO based on ETDRS criteria. Macular oedema with CMT of at least 300 µm by optical coherence tomography </p> <p><b>Exclusion criteria</b>: unstable medical status, previous treatment for DMO, history of vitreoretinal surgery, uncontrolled glaucoma; proliferative diabetic retinopathy with active neovascularisation, previous panretinal photocoagulation, presence of vitreomacular traction, history of systemic corticosteroids use in last 6 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: Intravitreal bevacizumab (1.25mg/0.05ml) and intravitreal triamcinolone acetonide (2mg/0.05ml) </p> <p><b>Comparator 1</b>: Intravitreal bevacizumab (1.25mg/0.05ml) </p> <p><b>Comparator 2</b>: intravitreal triamcinolone acetonide (2mg/0.05ml) </p> <p>Bevacizumab was given as 2 injections at 6‐week intervals. During follow‐up, all three groups received repeated bevacizumab injections when CMT was greater than 300 μm on OCT at 6 week intervals. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome:</b> </p> <p> <ul id="CD011599-lst1-0015"> <li> <p>Change in BCVA at 1 year (LogMAR chart)</p> </li> </ul> </p> <p><b>Secondary outcome</b> </p> <p> <ul id="CD011599-lst1-0016"> <li> <p>Change in CMT at 1 year (Stratus OCT 3; Carl Zeiss Meditec)</p> </li> </ul> </p> <p><b>Length of follow‐up</b>: 1 year </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial registration</b>: NCT01342159 </p> <p><b>Source of funding</b>: not reported </p> <p><b>Declaration of interest:</b> Quote "No conflicting relationship exists for any author." </p> <p><b>Date study conducted:</b> March 2008 to February 2010 (start date was March 2009 on clinical trials.gov) </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "Randomization was performed using a random block permutation method according to a computer‐generated randomization list. Block lengths varied randomly" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "The random allocation sequence was performed by a biostatistician. Details of the series were unknown to the investigators." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Authors do not state whether investigators or participants were masked to treatment allocation. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "Visual acuity assessment and OCT were performed by an optometrist who was blinded to the group status of the patients." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Nine study eyes did not complete the study. In the case of 3 eyes, it was because the person refused the intervention, reasons for the other 6 eyes lost to follow‐up was not stated. It was not reported which group these eyes were randomly allocated to. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>VA and CMT outcomes reported at 6 weeks and at 3, 6 and 12 months. Rates of cataract progression, ocular hypertension, vitreous haemorrhage, retinal detachment, endophthalmitis, increase in blood pressure and thromboembolic events were also recorded. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Both eyes being eligible to allocation in a single individual poses the theoretical potential to influence outcomes in the fellow eye via systemic absorption. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Maturi 2015 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design</b>: parallel group RCT </p> <p><b>Unit of randomisation</b>: participants were randomly allocated to treatment. For participants in whom both eyes were eligible, the right eye was randomised to combination therapy and the left eye was assigned to monotherapy. </p> <p><b>Number randomised</b>: </p> <p>Total: 40 eyes, 30 participants. 10 people had both eyes enrolled</p> <p>Intervention arms: 21 combination therapy (anti‐VEGF/steroid), 19 monotherapy (anti‐VEGF)</p> <p><b>Unit of analysis</b>: individual eyes </p> <p><b>Number analysed</b>: </p> <p>Total: 35 eyes</p> <p>1 year follow‐up on 18/21 eyes in anti‐VEGF/steroid group (2 withdrew, 1 lost to follow‐up) and 17/19 of anti‐VEGF group (1 withdrew, 1 lost to follow‐up). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country</b>: USA </p> <p><b>Mean age</b>: 61 years </p> <p><b>Sex</b>: 13 women; 17 men </p> <p><b>Underlying conditions</b>: DMO </p> <p><b>Inclusion criteria</b>: aged 18 years or older, BCVA scores between 24 and 78, early treatment of Diabetic Retinopathy Study letters (20/32–20/320 Snellen equivalent), and the presence of DMO (because of type 1 or 2 diabetes mellitus) with a CMT of greater than 250 μm measured by time‐domain OCT </p> <p><b>Exclusion criteria</b>: intravitreal anti‐VEGF injection within the previous 4 weeks, IVS injection within the previous 8 weeks, and macular laser within the previous 16 weeks, iris neovascularisation, poorly controlled diabetes mellitus (HbA1c &gt; 10 mg/dL), a known history of intraocular pressure increase because of corticosteroids that would not be adequately controlled with 2 topical glaucoma medications, and any condition that in the opinion of the investigator might compromise the results of the trial or preclude the participant from completing all study visits. Female participants needed a negative pregnancy test and the use of a contraceptive. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: intravitreal bevacizumab (1.25mg) and dexamethasone implant (0.7mg) </p> <p><b>Comparator</b>: intravitreal bevacizumab (1.25mg) </p> <p>Bevacizumab was given at baseline and 1 month, dexamethasone implant was given at 1 month. Bevacizumab injections were repeated at months 2, 3, 4, 6, 7, 8, 10, and 11 when the CMT &gt; 250 μm, and the ETDRS VA score was &lt; 80 letters (20/25); dexamethasone implants were re‐injected at months 5 and 9 according to the same criteria. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011599-lst1-0017"> <li> <p>Visual acuity (ETDRS letters) at 12 months</p> </li> <li> <p>Central subfield thickness (OCT) at 12 months</p> </li> <li> <p>Speed of visual improvement: time until gain 15 letters</p> </li> <li> <p>Number of injections required</p> </li> </ul> </p> <p><b>Length of follow‐up</b>: 1 year </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial registration</b>: not stated </p> <p><b>Source of funding</b>: supported by an investigator‐initiated trial grant from Allergan, Inc. The Leona M and Harry B Helmsley Charitable Trust provided funding for the statistical centre at the Jaeb Center for Health Research to conduct the statistical analyses. </p> <p><b>Declaration of interest:</b> Quote <b>"</b>R. K. Maturi, Allergan, Regeneron: Advisory Board; Ely Lilly, Jaeb Center for Health Research: consultant; Alcon, Alimera, Quark: subinvestigator; Allergan, Sanofi, Eyegate, Glaxosmithkline, Jaeb Center, Parexel, Santen: principal investigator and M. W. Stewart, Allergan, Regeneron: Advisory Board, Boehringer‐Ingelheim: consultant. The remaining authors have no conflicting interests to disclose." </p> <p><b>Date study conducted:</b> May 2011 to January 2012 </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Generation of the allocation sequence not reported.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment not reported.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants were masked to the treatment modality; investigators performing interventions were not. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not specified in publication.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The 12‐month evaluation was performed on 18 of 21 eyes in the combination group (2 withdrew and 1 was lost to follow‐up) and 17 of 19 eyes in the bevacizumab monotherapy group (1 withdrew and 1 was lost to follow‐up). The exact reasons for participants exiting the study early were not published. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>VA, central subfield thickness, injection load and safety outcomes were reported.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Both eyes being eligible to allocation in a single individual poses the theoretical potential to influence outcomes in the fellow eye via systemic absorption. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Neto 2017 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> parallel group RCT (8 clinical sites) </p> <p><b>Unit of randomisation:</b> people, one eye per person </p> <p><b>Number randomised:</b> </p> <p>142 (on trials registry entry) 111 reported in analyses</p> <p><b>Unit of analysis:</b> Individual eyes </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country:</b> Brazil </p> <p><b>Mean age</b>: not reported </p> <p><b>Sex</b>: 50 women; 61 men </p> <p><b>Underlying conditions:</b> diabetic macular oedema </p> <p>I<b>nclusion criteria:</b> </p> <p>18 years of age at least</p> <p>Diagnosis of diabetes mellitus (type 1 or type 2. any one of the following will be considered to be sufficient evidence that diabetes is present: </p> <p>Current regular use of insulin for the treatment of diabetes</p> <p>Current regular use of oral hypoglycaemic agents for the treatment of diabetes</p> <p>Diabetes as defined by American Diabetes Association (ADA)</p> <p>Symptoms of diabetes (polyuria, polydipsia, and unexplained weight loss) or eighth‐hour fasting plasma glucose &gt; 126 mg/dl </p> <p>Diabetic macular edema clinically observable associated with diabetic retinopathy:</p> <p>Without prior foveal treatment with laser therapy</p> <p>If photocoagulation or peripheral or macular laser, at least 3 months</p> <p>Absence of macular ischaemia by fluorescein angiography on baseline visit</p> <p>BCVA score between 20 letters (20/400 ETDRS) and 70 letters (20/40 ETDRS) in the study eye measured by the ETDRS method at qualification/baseline visit </p> <p>Retinal thickness &gt; 275 um by OCT</p> <p>One eye per participant will be chosen for the study. In case of both eye eligible, one eye will be randomised to be treated with study medication. The second eye can receive macular laser therapy at baseline or intravitreal injection after the protocol has finished. </p> <p>Taught hyaloid syndrome</p> <p><b>Exclusion criteria:</b> </p> <p>Uncontrolled systemic disease</p> <p>Initiation of medical therapy for diabetes or a change from oral hypoglycaemic agents to insulin therapy within 4 months prior to the qualification visit </p> <p>Renal failure requiring haemodialysis or peritoneal dialysis within 6 months prior to the qualification visit </p> <p>Any ocular condition in the study eye that in the opinion of the investigator would prevent a 2 lines improvement of visual acuity (e.g. severe macular ischaemia) </p> <p>Presence of branch retinal vein occlusion, central retinal vein occlusion, uveitis, pseudophakic cystoid oedema or any other condition in the study eye which could be contributing to macular oedema </p> <p>Presence of an epiretinal membrane in the study eye</p> <p>History of IOP elevation in response to steroid treatment in either eye</p> <p>History of glaucoma or optic nerve head change consistent with glaucoma damage</p> <p>Ocular hypertension requiring more than 1 anti‐glaucoma medication to maintain IOP &lt; 11mmhg at qualification visit </p> <p>Presence of anterior chamber intraocular lens in the study eye</p> <p>Active optic disc or retinal neovascularisation in the study eye at qualification visit </p> <p>Active or history of choroidal neovascularisation in the study eye</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention:</b> intravitreal bevacizumab (1.25mg/0.05ml) and intravitreal triamcinolone acetate (4mg/0.1ml) </p> <p><b>Comparator 1:</b> Intravitreal bevacizumab (1.25mg/0.05ml) </p> <p><b>Comparator 2:</b> intravitreal triamcinolone acetate (4mg/0.1ml) </p> <p>Pro re nata regimen: participants treated monthly unless BCVA was 20/30 and foveal thickness of 275 microns or less. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome:</b> </p> <p> <ul id="CD011599-lst1-0018"> <li> <p>BCVA (ETDRS)</p> </li> </ul> </p> <p><b>Secondary outcomes:</b> </p> <p> <ul id="CD011599-lst1-0019"> <li> <p>IOP measured by tonometry</p> </li> <li> <p>Retinal thickness measured by OCT</p> </li> </ul> </p> <p><b>Length of follow‐up:</b> 6 months (24 weeks) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial registration</b>: NCT00737971 </p> <p><b>Source of funding</b>: This work was supported in part by Sao Paulo Research Foundation. </p> <p><b>Declaration of interest:</b> Reported no relevant disclosures </p> <p><b>Date study conducted:</b> December 2012 to December 2013 </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote "the study participants were randomly assigned into groups of 30 subjects followed by a process of simple randomization with cards with equal probability (1:1:1)" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as "masked" but not enough information to judge how this was done</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as "masked" but not enough information to judge how this was done</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study was described as "masked" but not enough information to judge how this was done</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Clinical trials registry entry suggested 142 people enrolled but only 111 (87%) reported.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All outcomes on clinical trials registry entry reported.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Riazi‐Esfahani 2017 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design</b>: within‐person RCT </p> <p><b>Unit of randomisation</b>: one eye was randomised to monotherapy and the other eye assigned to combined therapy. </p> <p><b>Number randomised</b>: </p> <p>Total: 92 eyes of 46 participants</p> <p>46 eyes anti‐VEGF, 46 eyes anti‐VEGF/steroid</p> <p><b>Unit of analysis</b>: individual eyes </p> <p><b>Number analysed</b>: </p> <p>Total: 92 eyes at week 2, falling to 82 eyes at week 24</p> <p>Two participants lost to follow‐up. 3 progressed to proliferative retinopathy</p> <p>At 6 months:</p> <p>41 eyes in anti‐VEGF group</p> <p>41 eyes in anti‐VEGF/steroid group</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country</b>: Iran </p> <p><b>Mean age</b>: 62 years </p> <p><b>Sex</b>: 25 women; 21 men </p> <p><b>Underlying conditions</b>: diabetic macular oedema </p> <p><b>Inclusion criteria</b>: bilateral clinically significant DMO based on ETDRS criteria and central macular thickness of (CMT) &gt; 320 μm. </p> <p><b>Exclusion criteria</b>: proliferative diabetic retinopathy, a history of any treatment for DMO (panretinal or focal laser photocoagulation and anti‐VEGF or IVS), ocular surgery, glaucoma or ocular hypertension, monocularity, pregnancy, VA ≤ 20/320, significant media opacity, CMT ≤ 320 μm, and a serum creatinine level &gt; 3mg/dL. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention:</b> intravitreal bevacizumab (1.25mg/0.05ml) and intravitreal triamcinolone acetonide (1mg/0.025ml) </p> <p><b>Comparator:</b> intravitreal bevacizumab (1.25mg/0.05ml) </p> <p>Retreatments were performed at a 6‐week interval after reevaluation of the participants. Retreatment indications consisted of centrally involved macular oedema (more than 320 μm) based on OCT findings if VA was worse than 20/40. Retreatment was not performed if little or no oedema involving the centre of the macula or VA was ≥ 20/40 or any clinically significant adverse effect from prior treatment was reported. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011599-lst1-0020"> <li> <p>Mean change in BCVA at 24 weeks: Snellen chart</p> </li> <li> <p>CMT change at weeks 2, 4, 6, 12 and 24: SD‐OCT</p> </li> <li> <p>Injection ‐ related complications</p> </li> <li> <p>Number of injections</p> </li> </ul> </p> <p><b>Length of follow‐up</b>: 6 months (24 weeks) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial registration</b>: clinical trial registration IRCT ID: IRCT2014080818733N1 (retrospectively registered) </p> <p><b>Source of funding</b>: not reported </p> <p><b>Declaration of interest:</b> Quote "The authors declare that they have no conflict of interest." </p> <p><b>Date study conducted:</b> October 2014 to May 2015 (from clinical trials registry entry) </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomisation was performed by a random block permutation method according to a computer‐generated randomisation list. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Details of the series were unknown by the study investigators. A biostatistician performed random allocation sequencing. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single surgeon other than the study investigators ran all the procedures to maintain investigator masking </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>At each visit, certified examiners masked to both the randomisation and previous measurements determined visual acuity and performed OCT. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Five participants lost to follow‐up: 3 excluded due to progressing to high risk proliferative retinopathy before intervention; reasons for other 2 dropouts were unclear. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>VA and CMT outcomes reported at 6 weeks and at 3, 6 and 12 months. Rates of cataract progression, ocular hypertension, vitreous haemorrhage, retinal detachment, endophthalmitis, increase in blood pressure and thromboembolic events were also recorded. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Both eyes being eligible to allocation in a single individual poses the theoretical potential to influence outcomes in the fellow eye via systemic absorption. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Shoeibi 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design</b>: parallel group RCT </p> <p><b>Unit of randomisation</b>: participants were randomly allocated to treatment. In bilateral cases, each eye was randomised individually </p> <p><b>Number randomised</b>: </p> <p>Total: 115 eyes, 101 participants</p> <p>Intervention arms: 41 anti‐VEGF, 37 anti‐VEGF/steroid, 37 control eyes</p> <p><b>Unit of analysis</b>: individual eyes </p> <p><b>Number analysed</b>: </p> <p>Total: 115 eyes</p> <p>No study eyes lost to follow‐up</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country</b>: Iran </p> <p><b>Mean age</b>: 60 years </p> <p><b>Sex</b>: 44 women, 34 men </p> <p><b>Underlying conditions</b>: DMO refractory to laser treatment </p> <p><b>Inclusion criteria</b>: participants were from an earlier trial. These participants had refractory DMO that had not responded to macular laser treatment and had been previously allocated to 1 of the 3 treatment arms (anti‐VEGF, anti‐VEGF/steroid or sham injection). They had received 3 doses of anti‐VEGF (alone in the anti‐VEGF group or combined at the time of first injection with IVS in the anti‐VEGF/steroid group) at 6‐week intervals. As the beneficial effect of anti‐VEGF at 6 months was established, participants in the sham group also received anti‐VEGF according to the protocol but were not included in the current study. </p> <p><b>Exclusion criteria</b>: cataract surgery likely during the study period, significant media opacity precluding retinal view, presence of traction on the macula evidenced by OCT, monocularity and pregnancy. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: Intravitreal bevacizumab (1.25mg/0.05ml) and triamcinolone acetonide (2mg/0.05ml) </p> <p><b>Comparator:</b> Intravitreal bevacizumab (1.25mg/0.05ml) and sham injection </p> <p>Bevacizumab 3 loading doses at 6‐week intervals. After week 24, all study eyes could receive further bevacizumab on an as required basis. </p> <p>Triamcinolone acetonide was given in the first dose only.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011599-lst1-0021"> <li> <p>Change in CMT: OCT (Stratus OCT 3; Carl Zeiss Meditec)</p> </li> <li> <p>BCVA: Snellen chart converted into LogMAR</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> <p><b>Length of follow‐up</b>: 6 months (24 weeks) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial registration</b>: not stated </p> <p><b>Source of funding</b>: not reported </p> <p><b>Declaration of interest:</b> Quote "Conflicts of interest: none" </p> <p><b>Date study conducted:</b> November 2005 to September 2006 </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomisation was performed using a random block permutation method according to a computer‐generated randomisation list. The block lengths varied randomly. In bilateral cases, each eye was randomised individually. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A biostatistician performed the random allocation sequence and details of the series were unknown to the investigators </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants only were masked to the treatment modality.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>VA assessment and OCT were performed by optometrists who were masked to the groups.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One participant in the combined anti‐VEGF/steroid group developed vitreous haemorrhage after the third injection and was excluded from the study according to the 24‐week report. One participant in the control group died during the first 24 weeks of the study. The flow diagram of the study, where long‐term results are presented, does not make reference to these exclusions. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome measure was change in CMT measured on OCT. However, VA change was included as a secondary outcome </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Snellen chart was used for measurement of BCVA. However, inherent shortcomings of this chart, such as non‐geometric progression of letter size, variable number of letters per line and lack of a standardised scaling system, should be kept in mind. </p> <p>Both eyes being eligible to allocation in a single individual poses the theoretical potential to influence outcomes in the fellow eye via systemic absorption. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Soheilian 2012 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design</b>: parallel group RCT </p> <p><b>Unit of randomisation</b>: participants were randomly allocated to intervention. In bilateral cases each eye was randomised individually </p> <p><b>Number randomised</b>: </p> <p>Total: 150 eyes, 129 participants</p> <p>Intervention arms: 50 anti‐VEGF, 50 anti‐VEGF/steroid, 50 MPC</p> <p><b>Unit of analysis</b>: Individual eyes </p> <p><b>Number analysed</b>: </p> <p>Total: 113 eyes</p> <p>There were 21 bilateral cases: 2 bilateral MPC, 2 bilateral anti‐VEGF, 2 bilateral anti‐VEGF/steroid. 4 received anti‐VEGF for one eye and anti‐VEGF/steroid for the other, 4 participants had anti‐VEGF for one eye and MPC for the fellow eye, and the remaining 7 participants treated by anti‐VEGF/steroid for one eye and MPC for the other. </p> <p>Individual eyes:</p> <p>39 anti‐VEGF, 36 anti‐VEGF/steroid, 38 MPC</p> <p>Lost to follow‐up:</p> <p>12 anti‐VEGF, 13 anti‐VEGF/steroid, 12 MPC</p> <p>There were 25% of study eyes lost to follow‐up at 2 years,12% at 1 year. Investigators reported that visual acuity outcomes between those eyes that exited early were similar to those that completed follow up. However the methods of this analysis were not reported. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country</b>: Iran </p> <p><b>Mean age</b>: 61 years </p> <p><b>Sex</b>: 74 women, 76 men </p> <p><b>Underlying conditions</b>: DMO </p> <p><b>Inclusion criteria</b>: clinically significant DMO based on ETDRS criteria </p> <p><b>Exclusion criteria</b>: panretinal or focal laser photocoagulation, previous intraocular surgery or injection, history of glaucoma or ocular hypertension, VA between 20/40 and 20/ 300, presence of iris neovascularisation, high‐risk proliferative diabetic retinopathy, and significant media opacity, monocularity, pregnancy, raised serum creatinine, and uncontrolled diabetes mellitus </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: intravitreal bevacizumab (1.25mg/0.05ml) and triamcinolone acetonide (2mg/ 0.05ml) </p> <p><b>Comparator 1</b>: intravitreal bevacizumab (1.25mg/0.05ml) </p> <p><b>Comparator 2:</b> focal or modified grid laser </p> <p>The study eyes received re‐treatment with the initial intervention at 12 week intervals if there was persistent clinically significant macula oedema and BCVA was worse than 20/40. Bevacizumab re‐treatment was at a maximum frequency of 12 weeks, which is significantly less than the treatment interval in more recent trials. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011599-lst1-0022"> <li> <p>BCVA: Snellen chart converted into LogMAR letters</p> </li> <li> <p>CMT OCT (Zeiss, Dublin, CA)</p> </li> <li> <p>Injection related complications</p> </li> </ul> </p> <p>The primary outcome was change in BCVA at 6 months but change at 1 year and 2 years was also recorded. </p> <p><b>Length of follow‐up</b>: 2 years with review every 3 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial registration</b>: clinicaltrials.gov identifier: NCT00370669. </p> <p><b>Source of funding</b>: supported in part by Ophthalmic Research Center of Shahid Beheshti, University of Medical Sciences, Tehran, Iran </p> <p><b>Declaration of interest:</b> Quote: "Conflicts of interest: none" </p> <p><b>Date study conducted:</b> September 2005 to May 2007 </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomisation was performed using a random block permutation method according to a computer‐generated randomisation list. The block lengths varied randomly. In bilateral cases each eye was randomised individually </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A biostatistician performed random allocation sequence, and details of series were unknown to the study investigators. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Sham injections and laser were performed to ensure participants remained masked. Procedures were carried out by team members other than those assessing outcomes. However, those delivering treatment were not masked to treatment allocation. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Certified masked examiners performed BCVA and OCT measurements.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>38/50 (76%) of anti‐VEGF/steroid group followed up to 36 weeks.</p> <p>44/50 (88%) of anti‐VEGF group followed up to 36 weeks.</p> <p>43/50 (86%) of MPC group followed up to 36 weeks.</p> <p>Higher loss to follow‐up in anti‐VEGF/steroid group appeared to be related to adverse effects (cataract, neovascular glaucoma) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>VA and CMT outcomes were recorded. Not all safety outcomes were presented.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Snellen chart was used for measurement of BCVA. However, inherent shortcomings of this chart, such as non‐geometric progression of letter size, variable number of letters per line and lack of a standardised scaling system, should be kept in mind. </p> <p>Both eyes being eligible to allocation in a single individual poses the theoretical potential to influence outcomes in the fellow eye via systemic absorption. </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Synek 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Study design</b>: parallel group RCT using block permutation </p> <p><b>Unit of randomisation</b>: 1 eye included in the study, unclear how selection was carried out in cases of bilateral DMO </p> <p><b>Number randomised</b>: </p> <p>Total: 60 eyes, 60 participants</p> <p>Intervention arms: 30 anti‐VEGF, 30 anti‐VEGF/steroid</p> <p><b>Unit of analysis</b>: individual eyes </p> <p><b>Number analysed</b>: </p> <p>Total: 60 eyes, 60 participants</p> <p>Intervention arms: 30 anti‐VEGF, 30 anti‐VEGF/steroid</p> <p>To have a power of 90%, a level of significance equal<br> to 0.05 and an assumed standard deviation of 50 microns, a minimum sample size of 30 eyes for each arm was calculated to detect a 30% difference in CMT changes between the two treatment groups. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Country</b>: Czech Republic </p> <p><b>Mean age</b>: 60 years </p> <p><b>Sex</b>: 31 women, 29 men </p> <p><b>Underlying conditions</b>: DMO </p> <p><b>Inclusion criteria</b>: eyes with clinically significant macular oedema unresponsive to previous macular laser photocoagulation, with the last session being more than 3 months prior </p> <p><b>Exclusion criteria</b>: VA &gt; 20/40, history of cataract surgery within the past 6 months, prior intraocular injection or vitrectomy, glaucoma or ocular hypertension, proliferative diabetic retinopathy with high‐risk characteristics, vitreous haemorrhage, significant media opacity, and presence of traction on the macula. Monocular participants excluded. Pregnancy and raised serum creatinine level were also contraindications. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: intravitreal bevacizumab (1.25mg/0.05ml) and triamcinolone acetonide (2mg/0.05ml) </p> <p><b>Comparator</b>: intravitreal bevacizumab (1.25mg/0.05ml) </p> <p>3 injections of bevacizumab at 6‐week intervals. One injection of triamcinolone acetonide on first dose only </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD011599-lst1-0023"> <li> <p>Change in CMT at 6 months: OCT</p> </li> <li> <p>Change in BCVA at 6 months: Snellen chart converted to LogMAR</p> </li> <li> <p>Ocular adverse events: IOP rise, cataract progression, intraocular inflammation</p> </li> </ul> </p> <p><b>Length of follow‐up</b>: 6 months (24 weeks) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial registration</b>: not stated </p> <p><b>Source of funding</b>: not stated </p> <p><b>Declaration of interest:</b> Quote "The author has no proprietary interest in this study." </p> <p><b>Date study conducted:</b> not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomisation was performed using a random block permutation method according to a computer‐generated randomisation list. The block lengths varied randomly. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A biostatistician performed the random allocation sequence. Details of the series were unknown to the investigators. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants were masked to the treatment modality. Investigators performing interventions were not. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not stated whether outcome measures were assessed my masked investigators.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reported no cases lost to follow‐up.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome measure was change in CMT measured on OCT. However, VA change was included as a secondary outcome. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Snellen chart was used for measurement of BCVA. However, inherent shortcomings of this chart, such as non‐geometric progression of letter size, variable number of letters per line and lack of a standardised scaling system should be kept in mind. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>BCVA</b>: best corrected visual acuity; <b>CMT</b>: central macular thickness; <b>DMO</b>: diabetic macular oedema; <b>ETDRS</b>: Early Treatment Diabetic Retinopathy Study;<b>IOP</b>: intraocular pressure; <b>IVB</b>: intravitreal bevacizumab; <b>IVS</b>: intravitreal steroid; <b>LogMAR</b>: Logarithm of the Minimum Angle of Resolution; <b>MPC</b>: macular photocoagulation; <b>OCT</b>: optical coherence tomography; <b>RCT</b>: randomised controlled trial; <b>VA</b>: visual acuity; <b>VEGF</b>: vascular endothelial growth factor. </p> </div> </div> </p> </section> <section class="characteristicsOfExcludedStudies" lang=""> <div class="section-header" id="CD011599-sec2-0030"> <h3 class="title">Characteristics of excluded studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD011599-sec2-0029" class="jump-to">included studies</a></li> <li><a href="#CD011599-sec2-0031" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reason for exclusion</p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011599-bbs2-0009">Faghihi 2008</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient length of follow‐up (16 weeks)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011599-bbs2-0010">Sheth 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient length of follow‐up (6 weeks)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011599-bbs2-0011">Soheilian 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient length of follow‐up (12 weeks)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011599-bbs2-0012">Wang 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient length of follow‐up (12 weeks)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD011599-bbs2-0013">Yu 2018</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient length of follow‐up (4 weeks)</p> </td> </tr> </tbody> </table> </div> </p> </section> <section class="characteristicsOfOngoingStudies" lang=""> <div class="section-header" id="CD011599-sec2-0031"> <h3 class="title">Characteristics of ongoing studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD011599-sec2-0029" class="jump-to">included studies</a></li> <li><a href="#CD011599-sec2-0030" class="jump-to">excluded studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT03126786 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Suprachoroidal CLS‐TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema (TYBEE) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Study design:</b> parallel group RCT </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>71 people with DMO</p> <p><b>Inclusion criteria:</b> </p> <p> <ul id="CD011599-lst1-0024"> <li> <p>Clinical diagnosis of type 1 or type 2 DM</p> </li> <li> <p>DME with central involvement (&gt; 300 µm in the central subfield on spectral‐domain optical coherence tomography (SD‐OCT)), in the study eye </p> </li> <li> <p>ETDRS BCVA score of ≥ 20 letters read and ≤ 70 letters read in the study eye</p> </li> <li> <p>Naïve to local pharmacologic treatment for DMO in the study eye</p> </li> </ul> </p> <p><b>Exclusion criteria:</b> </p> <p> <ul id="CD011599-lst1-0025"> <li> <p>IOP &gt; 21 mmHg in the study eye at Visit 1 (Day ‐30 to ‐1); participants are not excluded if IOP is &lt; 22 mmHg in the study eye with no more than 1 IOP lowering medication </p> </li> <li> <p>Any previous treatment in the study eye with an ocular corticosteroid implant</p> </li> <li> <p>Has significant media opacity precluding evaluation of retina and vitreous in the study eye. </p> </li> <li> <p>History of glaucoma or optic nerve head change consistent with glaucoma damage</p> </li> <li> <p>History of glaucoma surgery</p> </li> <li> <p>History of clinically significant IOP elevation in response to corticosteroid treatment ("steroid responder") </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention:</b> intravitreal aflibercept (2mg/0.05mL) plus suprachoroidal injection of triamcinolone acetonide (40mg/mL) </p> <p><b>Comparator:</b> intravitreal aflibercept (2mg/0.05mL) plus sham injection </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome:</b> </p> <p>Mean change from baseline in BCVA at 6 months</p> <p><b>Secondary outcome:</b> </p> <p>Mean change from baseline in central subfield thickness at 6 months (measured by OCT)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>July 2017</p> <p>End date: April 2018</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>https://clinicaltrials.gov/show/<a href="references#CD011599-bbs2-0014">NCT03126786</a> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Suprachoroidal rather than intravitreal delivery of triamcinolone</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">UMIN000021630 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Anti‐VEGF and steroid combination therapy for diabetic macular oedema</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Study design</b>: parallel non‐masked prospective randomised controlled trial </p> <p><b>Unit of randomisation</b>: not specified </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Country</b>: Japan </p> <p><b>Underlying conditions</b>: diabetic macular oedema </p> <p><b>Inclusion criteria</b>: &gt; 20 years of age, clinically significant DMO refractory to laser treatment, Japanese LogMAR visual acuity 1.52‐1.22, CMT &gt; 300 µm </p> <p><b>Exclusion criteria</b>: treated with macular laser within 3 months, ischaemic maculopathy, vitreomacular traction, proliferative diabetic retinopathy, glaucoma, optic neuropathy, vitrectomy, phakic eye, previous intravitreal or subtenon steroid injection, steroid responder, heart failure, cerebral vascular disease,hematological disease, tumour, concurrent systemic steroids, renal failure (&gt; CKD S3), grade III hypertension, HbA1c NGSP over 10%. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention 1</b>: 2 months after loading doses of intravitreal ranibizumab injections, intravitreal ranibizumab is continued </p> <p><b>Intervention 2</b>: 2 months after loading doses of intravitreal ranibizumab injections, an intravitreal triamcinolone injection is delivered </p> <p>The exact treatment schedule and retreatment criteria are not specified.</p> <p><b>Length of follow‐up</b>: not specified </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The primary outcome is the number of ranibizumab injections required over duration of trial. The length of the trial is not specified. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>27 March 2016</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/PWZGZ55BMRYHK5LJNZYGCZ3PNJZA/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024947" target="_blank">upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000024947</a> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial registration</b>: <a href="references#CD011599-bbs2-0015">UMIN000021630</a> </p> <p><b>Source of funding</b>: Self funded </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CKD</b>: chronic kidney disease; <b>DMO</b>: diabetic macular oedema; <b>ETDRS</b>: Early Treatment Diabetic Retinopathy Study;<b>Hb1Ac</b>: glycated haemoglobin; <b>LogMAR</b>: Logarithm of the Minimum Angle of Resolution; <b>NGSP</b>: National Glycohemoglobin Standardization Program; <b>OCT</b>: optical coherence tomography;<b>VEGF</b>: vascular endothelial growth factor. </p> </div> </div> </p> </section> </section> <section class="dataAndAnalyses" id="dataAndAnalyses"> <section class="dataAndAnalyses" lang="en"> <div class="section-header section-collapse-header" id="CD011599-sec1-0011"> <h2 class="title section-collapse-title">Data and analyses<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <div class="table" id="CD011599-tbl-0004"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Anti‐VEGF and steroid versus anti‐VEGF alone</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Mean change in visual acuity at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>618</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.88 [‐2.56, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00101"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-01.png?filename=nCD011599-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%201%20Mean%20change%20in%20visual%20acuity%20at%206%20months.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.1</div> </div> <hr class="top"><img data-id="CD011599-fig-00101" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-01.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 1 Mean change in visual acuity at 6 months."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 1 Mean change in visual acuity at 6 months. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Mean change in visual acuity at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>188</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.29 [‐6.03, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00102"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-02.png?filename=nCD011599-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%202%20Mean%20change%20in%20visual%20acuity%20at%201%20year.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.2</div> </div> <hr class="top"><img data-id="CD011599-fig-00102" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-02.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 2 Mean change in visual acuity at 1 year."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 2 Mean change in visual acuity at 1 year. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Mean change in visual acuity at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00103"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-03.png?filename=nCD011599-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%203%20Mean%20change%20in%20visual%20acuity%20at%202%20years.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.3</div> </div> <hr class="top"><img data-id="CD011599-fig-00103" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-03.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 3 Mean change in visual acuity at 2 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 3 Mean change in visual acuity at 2 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Mean change in central macular thickness at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>617</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐19.73 [‐40.47, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00104"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-04.png?filename=nCD011599-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%204%20Mean%20change%20in%20central%20macular%20thickness%20at%206%20months.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.4</div> </div> <hr class="top"><img data-id="CD011599-fig-00104" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-04.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 4 Mean change in central macular thickness at 6 months."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 4 Mean change in central macular thickness at 6 months. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Mean change in central macular thickness at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>188</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.20 [‐37.14, 37.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00105"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-05.png?filename=nCD011599-CMP-001-05.ppt&amp;title=1.5&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%205%20Mean%20change%20in%20central%20macular%20thickness%20at%201%20year.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.5</div> </div> <hr class="top"><img data-id="CD011599-fig-00105" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-05.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 5 Mean change in central macular thickness at 1 year."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 5 Mean change in central macular thickness at 1 year. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Mean change in central macular thickness at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00106"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-06.png?filename=nCD011599-CMP-001-06.ppt&amp;title=1.6&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%206%20Mean%20change%20in%20central%20macular%20thickness%20at%202%20years.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.6</div> </div> <hr class="top"><img data-id="CD011599-fig-00106" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-06.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 6 Mean change in central macular thickness at 2 years."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 6 Mean change in central macular thickness at 2 years. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00107"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-07.png?filename=nCD011599-CMP-001-07.ppt&amp;title=1.7&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%207%20Adverse%20events.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.7</div> </div> <hr class="top"><img data-id="CD011599-fig-00107" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-07.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 7 Adverse events."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 7 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.1 All</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>635</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.66 [3.62, 8.84]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.2 Significant intraocular inflammation</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>635</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.53 [0.05, 5.08]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.3 Development of cataract</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>635</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.49 [2.87, 19.60]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.4 Raised intraocular pressure</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>635</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.13 [4.67, 14.16]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.5 Systemic adverse events</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>103</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.32 [0.61, 2.86]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Need for glaucoma drainage surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00108"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-08.png?filename=nCD011599-CMP-001-08.ppt&amp;title=1.8&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%208%20Need%20for%20glaucoma%20drainage%20surgery.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.8</div> </div> <hr class="top"><img data-id="CD011599-fig-00108" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-08.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 8 Need for glaucoma drainage surgery."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 8 Need for glaucoma drainage surgery. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011599-tbl-0005"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Anti‐VEGF and steroid versus macular laser</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Mean change in visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00201"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-002-01.png?filename=nCD011599-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20macular%20laser%2C%20Outcome%201%20Mean%20change%20in%20visual%20acuity.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.1</div> </div> <hr class="top"><img data-id="CD011599-fig-00201" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-01.png" alt="Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 1 Mean change in visual acuity."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 1 Mean change in visual acuity. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 6 months</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 1 year</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3 2 years</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Mean change in central macular thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00202"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-002-02.png?filename=nCD011599-CMP-002-02.ppt&amp;title=2.2&amp;caption=Comparison%202%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20macular%20laser%2C%20Outcome%202%20Mean%20change%20in%20central%20macular%20thickness.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.2</div> </div> <hr class="top"><img data-id="CD011599-fig-00202" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-02.png" alt="Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 2 Mean change in central macular thickness."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 2 Mean change in central macular thickness. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 6 months</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 1 year</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.3 2 years</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00203"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-002-03.png?filename=nCD011599-CMP-002-03.ppt&amp;title=2.3&amp;caption=Comparison%202%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20macular%20laser%2C%20Outcome%203%20Adverse%20events.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.3</div> </div> <hr class="top"><img data-id="CD011599-fig-00203" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-03.png" alt="Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 3 Adverse events."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 3 Adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 All</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 Development of cataract</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.3 Raised intraocular pressure</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011599-tbl-0006"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Anti‐VEGF and steroid versus steroid alone</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Mean change in visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00301"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-003-01.png?filename=nCD011599-CMP-003-01.ppt&amp;title=3.1&amp;caption=Comparison%203%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20steroid%20alone%2C%20Outcome%201%20Mean%20change%20in%20visual%20acuity.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.1</div> </div> <hr class="top"><img data-id="CD011599-fig-00301" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-01.png" alt="Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 1 Mean change in visual acuity."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 1 Mean change in visual acuity. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 6 months</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 1 year</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Mean change in central macular thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00302"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-003-02.png?filename=nCD011599-CMP-003-02.ppt&amp;title=3.2&amp;caption=Comparison%203%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20steroid%20alone%2C%20Outcome%202%20Mean%20change%20in%20central%20macular%20thickness.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.2</div> </div> <hr class="top"><img data-id="CD011599-fig-00302" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-02.png" alt="Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 2 Mean change in central macular thickness."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 2 Mean change in central macular thickness. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 6 months</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 1 year</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Raised intraocular pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>145</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.33 [0.11, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD011599-fig-00303"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-003-03.png?filename=nCD011599-CMP-003-03.ppt&amp;title=3.3&amp;caption=Comparison%203%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20steroid%20alone%2C%20Outcome%203%20Raised%20intraocular%20pressure.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.3</div> </div> <hr class="top"><img data-id="CD011599-fig-00303" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-03.png" alt="Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 3 Raised intraocular pressure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 3 Raised intraocular pressure. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> </section> </section> <div class="figures-list"> <div class="figure" id="CD011599-fig-0001"> <img data-id="CD011599-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG01.png" alt="Study flow diagram."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-fig-0001" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-AFig-FIG01.png?filename=nCD011599-AFig-FIG01.ppt&amp;title=1&amp;caption=Study%20flow%20diagram.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0002"><img data-id="CD011599-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG02.png" alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-fig-0002" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-AFig-FIG02.png?filename=nCD011599-AFig-FIG02.ppt&amp;title=2&amp;caption=Risk%20of%20bias%20graph%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20presented%20as%20percentages%20across%20all%20included%20studies.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0003"><img data-id="CD011599-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG03.png" alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-fig-0003" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-AFig-FIG03.png?filename=nCD011599-AFig-FIG03.ppt&amp;title=3&amp;caption=Risk%20of%20bias%20summary%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20for%20each%20included%20study.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG03.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0004"><img data-id="CD011599-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG04.png" alt="Forest plot of comparison: 1 Anti‐VEGF and steroid versus anti‐VEGF alone, outcome: 1.2 Mean change in visual acuity at 1 year [VA letters]."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anti‐VEGF and steroid versus anti‐VEGF alone, outcome: 1.2 Mean change in visual acuity at 1 year [VA letters]. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-fig-0004" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-AFig-FIG04.png?filename=nCD011599-AFig-FIG04.ppt&amp;title=4&amp;caption=Forest%20plot%20of%20comparison%3A%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20outcome%3A%201.2%20Mean%20change%20in%20visual%20acuity%20at%201%20year%20%5BVA%20letters%5D.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG04.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0005"><img data-id="CD011599-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG05.png" alt="Forest plot of comparison: 1 anti‐VEGF/steroid versus anti‐VEGF, outcome: 1.5 Mean change in central macular thickness at 1 year [μm]."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 anti‐VEGF/steroid versus anti‐VEGF, outcome: 1.5 Mean change in central macular thickness at 1 year [μm]. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-fig-0005" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-AFig-FIG05.png?filename=nCD011599-AFig-FIG05.ppt&amp;title=5&amp;caption=Forest%20plot%20of%20comparison%3A%201%20anti%E2%80%90VEGF%2Fsteroid%20versus%20anti%E2%80%90VEGF%2C%20outcome%3A%201.5%20Mean%20change%20in%20central%20macular%20thickness%20at%201%20year%20%5B%CE%BCm%5D.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG05.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-0006"><img data-id="CD011599-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG06.png" alt="Forest plot of comparison: 1 Anti‐VEGF and steroid versus anti‐VEGF alone, outcome: 1.7 Adverse events."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anti‐VEGF and steroid versus anti‐VEGF alone, outcome: 1.7 Adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-fig-0006" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-AFig-FIG06.png?filename=nCD011599-AFig-FIG06.ppt&amp;title=6&amp;caption=Forest%20plot%20of%20comparison%3A%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20outcome%3A%201.7%20Adverse%20events.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-AFig-FIG06.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00101"><img data-id="CD011599-fig-00101" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-01.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 1 Mean change in visual acuity at 6 months."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 1 Mean change in visual acuity at 6 months. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00101" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-01.png?filename=nCD011599-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%201%20Mean%20change%20in%20visual%20acuity%20at%206%20months.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00102"><img data-id="CD011599-fig-00102" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-02.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 2 Mean change in visual acuity at 1 year."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 2 Mean change in visual acuity at 1 year. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00102" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-02.png?filename=nCD011599-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%202%20Mean%20change%20in%20visual%20acuity%20at%201%20year.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00103"><img data-id="CD011599-fig-00103" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-03.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 3 Mean change in visual acuity at 2 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 3 Mean change in visual acuity at 2 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00103" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-03.png?filename=nCD011599-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%203%20Mean%20change%20in%20visual%20acuity%20at%202%20years.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00104"><img data-id="CD011599-fig-00104" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-04.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 4 Mean change in central macular thickness at 6 months."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 4 Mean change in central macular thickness at 6 months. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00104" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-04.png?filename=nCD011599-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%204%20Mean%20change%20in%20central%20macular%20thickness%20at%206%20months.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00105"><img data-id="CD011599-fig-00105" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-05.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 5 Mean change in central macular thickness at 1 year."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 5 Mean change in central macular thickness at 1 year. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00105" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-05.png?filename=nCD011599-CMP-001-05.ppt&amp;title=1.5&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%205%20Mean%20change%20in%20central%20macular%20thickness%20at%201%20year.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00106"><img data-id="CD011599-fig-00106" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-06.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 6 Mean change in central macular thickness at 2 years."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 6 Mean change in central macular thickness at 2 years. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00106" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-06.png?filename=nCD011599-CMP-001-06.ppt&amp;title=1.6&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%206%20Mean%20change%20in%20central%20macular%20thickness%20at%202%20years.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00107"><img data-id="CD011599-fig-00107" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-07.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 7 Adverse events."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 7 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00107" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-07.png?filename=nCD011599-CMP-001-07.ppt&amp;title=1.7&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%207%20Adverse%20events.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00108"><img data-id="CD011599-fig-00108" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-08.png" alt="Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 8 Need for glaucoma drainage surgery."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF and steroid versus anti‐VEGF alone, Outcome 8 Need for glaucoma drainage surgery. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00108" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-001-08.png?filename=nCD011599-CMP-001-08.ppt&amp;title=1.8&amp;caption=Comparison%201%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20anti%E2%80%90VEGF%20alone%2C%20Outcome%208%20Need%20for%20glaucoma%20drainage%20surgery.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-001-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00201"><img data-id="CD011599-fig-00201" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-01.png" alt="Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 1 Mean change in visual acuity."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 1 Mean change in visual acuity. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00201" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-002-01.png?filename=nCD011599-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20macular%20laser%2C%20Outcome%201%20Mean%20change%20in%20visual%20acuity.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00202"><img data-id="CD011599-fig-00202" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-02.png" alt="Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 2 Mean change in central macular thickness."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 2 Mean change in central macular thickness. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00202" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-002-02.png?filename=nCD011599-CMP-002-02.ppt&amp;title=2.2&amp;caption=Comparison%202%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20macular%20laser%2C%20Outcome%202%20Mean%20change%20in%20central%20macular%20thickness.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00203"><img data-id="CD011599-fig-00203" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-03.png" alt="Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 3 Adverse events."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Anti‐VEGF and steroid versus macular laser, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00203" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-002-03.png?filename=nCD011599-CMP-002-03.ppt&amp;title=2.3&amp;caption=Comparison%202%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20macular%20laser%2C%20Outcome%203%20Adverse%20events.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-002-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00301"><img data-id="CD011599-fig-00301" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-01.png" alt="Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 1 Mean change in visual acuity."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 1 Mean change in visual acuity. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00301" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-003-01.png?filename=nCD011599-CMP-003-01.ppt&amp;title=3.1&amp;caption=Comparison%203%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20steroid%20alone%2C%20Outcome%201%20Mean%20change%20in%20visual%20acuity.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00302"><img data-id="CD011599-fig-00302" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-02.png" alt="Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 2 Mean change in central macular thickness."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 2 Mean change in central macular thickness. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00302" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-003-02.png?filename=nCD011599-CMP-003-02.ppt&amp;title=3.2&amp;caption=Comparison%203%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20steroid%20alone%2C%20Outcome%202%20Mean%20change%20in%20central%20macular%20thickness.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD011599-fig-00303"><img data-id="CD011599-fig-00303" src="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-03.png" alt="Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 3 Raised intraocular pressure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Anti‐VEGF and steroid versus steroid alone, Outcome 3 Raised intraocular pressure. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-fig-00303" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/ppt/CDSR/CD011599/image_n/nCD011599-CMP-003-03.png?filename=nCD011599-CMP-003-03.ppt&amp;title=3.3&amp;caption=Comparison%203%20Anti%E2%80%90VEGF%20and%20steroid%20versus%20steroid%20alone%2C%20Outcome%203%20Raised%20intraocular%20pressure.&amp;citation=Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser%E2%80%90Bell S. Anti%E2%80%90vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews 2018, 4. Art. No.: CD011599. DOI: http://dx.doi.org/10.1002/14651858.CD011599.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD011599.pub2/media/CDSR/CD011599/image_n/nCD011599-CMP-003-03.png">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD011599-tbl-0001" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid versus intravitreal anti‐VEGF for diabetic macular oedema</span></div> <tbody> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Intravitreal anti‐VEGF plus intravitreal steroid versus intravitreal anti‐VEGF for diabetic macular oedema</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population</b>: adults with centre‐involving diabetic macular oedema </p> <p><b>Settings</b>: eye care clinic </p> <p><b>Intervention</b>: intravitreal anti‐VEGF plus intravitreal steroid (anti‐VEGF/steroid) </p> <p><b>Comparison</b>: intravitreal anti‐VEGF </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="center" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks*</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>No. of eyes<br> (studies)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Certainty of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Anti‐VEGF alone</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Anti‐VEGF/steroid</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Mean change in visual acuity at 1 year</b> </p> <p><b>(number of letters read on logMAR chart)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean visual acuity gain at 1 year ranged from 4.9 to 10.5 letters in the anti‐VEGF alone groups </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean number of letters read was on average 2.29 fewer in the anti‐VEGF/steroid group (95% CI −6.03 to 1.45) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>188</p> <p>(3)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low<sup>a</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Mean change in central macular thickness at 1 year</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean reduction in central macular thickness at 1 year ranged from −30 μm to −179 μm in the anti‐VEGF alone groups </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean reduction in central macular thickness was on average 0.20 μm greater in the anti‐VEGF/steroid groups (95% CI −37.14 to 37.53) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>188</p> <p>(3)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low<sup>a</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Significant intraocular inflammation at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>6 per 1000</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>3 per 1000</p> <p>(0 to 30 per 1000)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto OR 0.53 (0.05 to 5.08)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>635</p> <p>(8)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Very low<sup>b</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Only 3 events</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Development of cataract at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>3 per 1000</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>22 per 1000</p> <p>(9 to 56 per 1000)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto OR 7.49 (2.87 to 19.60)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>635</p> <p>(8)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Moderate<sup>c</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NB: significant cataract progression may occur in the second year of intravitreal steroid use. </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Raised intraocular pressure at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>6 per 1000</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>47 per 1000</p> <p>(27 to 79 per 1000)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto OR 8.13 (4.67 to 14.16)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>635</p> <p>(8)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Moderate<sup>c</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 participant needed glaucoma surgery in the anti‐VEGF/steroid group.<b>This outcome occurred only in 1 study</b>. The threshold for glaucoma drainage surgery was not specified. </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Systemic adverse events at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>400 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>468 per 1000</p> <p>(289 to 1000)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto OR 1.32</p> <p>(95% CI 0.61 to 2.86)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>103</p> <p>(1)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low<sup>d</sup> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quality of life at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="top" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention.<br> <b>CI</b>: confidence interval; <b>RR</b>: risk ratio; <b>MD</b>: mean difference; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br> <b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br> <b>Low‐certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br> <b>Very low‐certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of risk of bias and by one level because of imprecision.<br> <sup>b</sup>Downgraded one level because of risk of bias, and two levels for imprecision as there were very few events. </p> <p><sup>c</sup>Downgraded one level because of risk of bias </p> <p><sup>d</sup>Downgraded two levels for imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid versus intravitreal anti‐VEGF for diabetic macular oedema</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-tbl-0001" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011599-tbl-0002" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>&nbsp;<span class="table-title">Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus macular laser for diabetic macular oedema</span></div> <tbody> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>Intravitreal bevacizumab plus intravitreal steroid versus macular laser for diabetic macular oedema </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population</b>: adults with centre‐involving diabetic macular oedema </p> <p><b>Setting</b>: eye care clinic </p> <p><b>Intervention</b>: intravitreal bevacizumab plus intravitreal steroid (anti‐VEGF/steroid) </p> <p><b>Comparison</b>: macular laser </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="center" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks*</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>No of eyes<br> (studies)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Certainty of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Macular laser</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Anti‐VEGF/steroid</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Mean change in visual acuity at 1 year</b> </p> <p><b>(number of letters read on logMAR chart)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean visual acuity gain at 1 year was 1 letter with a standard deviation of 17 letters in the laser comparator group </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean number of letters read was 4.00 more in the anti‐VEGF/steroid group (95% CI −2.70 to 10.70) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low<sup>a</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Gain or loss of 10 or more letters visual acuity at 1 year</b> </p> </td> <td align="" valign="top" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Mean change in central macular thickness at 1 year</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean change in central macular thickness at 1 year was an increase of 6 μm with a standard deviation of 36 microns in the laser comparator group </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean reduction in central macular thickness was on average 16 μm greater in the anti‐VEGF/steroid group (95% CI −68.93 to 36.93) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low<sup>a</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Significant intraocular inflammation at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="top" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Development of cataract at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>20 per 1000</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>85 per 1000</p> <p>(20 to 301 per 1000)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto OR 4.58 (0.99 to 21.10)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Very low<sup>b</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Raised Intraocular Pressure at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>1 per 1000</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>9 per 1000</p> <p>(3 to 31 per 1000)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto OR 9.49 (2.86 to 31.51)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Very low<sup>b</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There was 1 participant who needed glaucoma drainage surgery in the anti‐VEGF/steroid group. Threshold for glaucoma drainage surgery not specified in the included study. </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Systemic adverse events at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quality of life at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="top" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention.<br> <b>CI</b>: confidence interval; <b>RR</b>: risk ratio; <b>MD</b>: mean difference; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br> <b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br> <b>Low‐certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br> <b>Very low‐certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of risk of bias and by one level due to imprecision. </p> <p><sup>b</sup>Downgraded one level because of risk of bias and by two levels due to imprecision (only 1 event in the comparator group). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>&nbsp;<span class="table-title">Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus macular laser for diabetic macular oedema</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-tbl-0002" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011599-tbl-0003" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>&nbsp;<span class="table-title">Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus intravitreal steroid for diabetic macular oedema</span></div> <tbody> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>Intravitreal bevacizumab plus intravitreal steroid compared with intravitreal steroid for diabetic macular oedema </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population</b>: adults with centre‐involving diabetic macular oedema </p> <p><b>Setting</b>: eye care clinic </p> <p><b>Intervention</b>: intravitreal bevacizumab plus intravitreal steroid (anti‐VEGF/steroid) </p> <p><b>Comparison</b>: intravitreal steroid (IVS) </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="center" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks*</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>No of eyes<br> (studies)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Certainity of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>IVS</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Anti‐VEGF/steroid</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Mean change in visual acuity at 1 year</b> </p> <p><b>(number of letters read on logMAR chart)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean visual acuity at 1 year was 24.5 letters in the IVS comparator group</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean number of letters read was on average 0 letters higher (i.e same) in the anti‐VEGF/steroid group (95% CI ‐6.1 to 6.1) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>73</p> <p>(1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low<sup>a</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>SD not reported for change in visual acuity so difference in visual acuity at 1 year reported </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Gain or loss of 10 or more letters visual acuity at 1 year</b> </p> </td> <td align="" valign="top" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Mean change in central macular thickness at 1 year</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean central macular thickness was 249 μm in the IVS comparator group at 1 year</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean central macular thickness was 9 μm less in the anti‐VEGF/steroid group (‐39.87μm less to 21.87μm more) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not estimable</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>73</p> <p>(1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low<sup>a</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>SD not reported for change so difference in final value reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Significant intraocular inflammation at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="top" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Development of cataract at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="top" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Raised intraocular pressure at 1 year at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>108 per 1000</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>83 per 1000</p> <p>(19 to 301 per 1000)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto OR 0.75 (0.16 to 3.55)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>73</p> <p>(1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Very Low<sup>b</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Systemic adverse events at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quality of life at follow‐up (from 6 months onwards)</b> </p> </td> <td align="" valign="top" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>The <b>assumed risk</b> is the control group risk across studies. The <b>corresponding risk</b> is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention.<br> <b>CI</b>: confidence interval; <b>RR</b>: risk ratio; <b>MD</b>: mean difference; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br> <b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br> <b>Low‐certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br> <b>Very low‐certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of risk of bias and by one level for imprecision. </p> <p><sup>b</sup>Downgraded one level because of risk of bias and by two levels for imprecision (very few events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>&nbsp;<span class="table-title">Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus intravitreal steroid for diabetic macular oedema</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-tbl-0003" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011599-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">Adverse events</span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Significant ocular inflammation</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Development of cataract</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Raised intraocular Pressure</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Need for glaucoma drainage surgery</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sample size</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Intravitreal anti‐VEGF + steroid</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0002">Lim 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>36</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0003">Maturi 2015</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>20</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0001">DRCRnet U 2018</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>19</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>65</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0004">Neto 2017</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>34</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0005">Riazi‐Esfahani 2017</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>41</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0006">Shoeibi 2013</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>37</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0007">Soheilian 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0008">Synek 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Total</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>54</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>313</p> </td> </tr> <tr> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Intravitreal anti‐VEGF</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0002">Lim 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>38</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0003">Maturi 2015</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>19</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0001">DRCRnet U 2018</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>64</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0004">Neto 2017</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>39</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0005">Riazi‐Esfahani 2017</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>41</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0006">Shoeibi 2013</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>41</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0007">Soheilian 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0008">Synek 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Total</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>322</p> </td> </tr> <tr> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Intravitreal steroid</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0002">Lim 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>37</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0003">Maturi 2015</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0001">DRCRnet U 2018</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0004">Neto 2017</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>38</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0005">Riazi‐Esfahani 2017</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0006">Shoeibi 2013</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0007">Soheilian 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0008">Synek 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Total</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>75</p> </td> </tr> <tr> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Macular laser</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0002">Lim 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0003">Maturi 2015</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0001">DRCRnet U 2018</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0004">Neto 2017</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0005">Riazi‐Esfahani 2017</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0006">Shoeibi 2013</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0007">Soheilian 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD011599-bbs2-0008">Synek 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Total</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>—</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">Adverse events</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/full#CD011599-tbl-0007" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011599-tbl-0004" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Anti‐VEGF and steroid versus anti‐VEGF alone</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Mean change in visual acuity at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>618</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.88 [‐2.56, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Mean change in visual acuity at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>188</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.29 [‐6.03, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Mean change in visual acuity at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Mean change in central macular thickness at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>617</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐19.73 [‐40.47, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Mean change in central macular thickness at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>188</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.20 [‐37.14, 37.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Mean change in central macular thickness at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.1 All</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>635</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.66 [3.62, 8.84]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.2 Significant intraocular inflammation</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>635</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.53 [0.05, 5.08]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.3 Development of cataract</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>635</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.49 [2.87, 19.60]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.4 Raised intraocular pressure</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>635</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.13 [4.67, 14.16]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.5 Systemic adverse events</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>103</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.32 [0.61, 2.86]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Need for glaucoma drainage surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Anti‐VEGF and steroid versus anti‐VEGF alone</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-tbl-0004" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011599-tbl-0005" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Anti‐VEGF and steroid versus macular laser</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Mean change in visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 6 months</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 1 year</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3 2 years</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Mean change in central macular thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 6 months</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 1 year</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.3 2 years</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 All</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 Development of cataract</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.3 Raised intraocular pressure</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Anti‐VEGF and steroid versus macular laser</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-tbl-0005" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD011599-tbl-0006" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Anti‐VEGF and steroid versus steroid alone</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Mean change in visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 6 months</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 1 year</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Mean change in central macular thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.1 6 months</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.2 1 year</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Raised intraocular pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>145</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.33 [0.11, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Anti‐VEGF and steroid versus steroid alone</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD011599.pub2/references#CD011599-tbl-0006" class="tableList">Navigate to table in Review</a></div> </div> </div> <section class="translation-notes-modal" style="display: none" data-modal-title="Translation notes" data-modal-class="translation-notes" data-ok-btn-selector=".ok-btn"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011599-note-1205">Español</a> </li> <li class="section-language"> <a class="" href="ms#CD011599-note-1204">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011599-note-1203">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" id="citeProcText" data-load-error="Unable to load citation data"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a href="#" class="addthis_button_citeulike at300b btn btn-link">CiteULike</a></li> <li><a href="#" class="addthis_button_mendeley at300b btn btn-link">Mendeley</a></li> <li><a href="#" class="citation-btn-refworks at300b btn btn-link" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <h4>Copy or download citation</h4> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button type="button" class="btn btn-link">Plain text</button></li> <li class="citation-option" data-option="endnote"><button type="button" class="btn btn-link">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button type="button" class="btn btn-link">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button type="button" class="btn btn-link">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button type="button" class="btn btn-link">BibteX</button></li> </nav> <div class="citation-content"> <pre id="citationContent" tabindex="0" data-load-error="Unable to load citation data"></pre> </div> <div class="clearfix"> <form class="download-citation-form" method="GET" target="citation-download-iframe" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=citation-citeproc&p_p_cacheability=cacheLevelPage&p_p_col_id=column-1&p_p_col_count=1"> <input type="hidden" id="siteId" name="siteId" value="" /> <input type="hidden" id="downloadType" name="downloadType" value="" /> <input type="hidden" id="style" name="style" value="" /> <input type="hidden" id="articleId" name="articleId" value="" /> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay" /><input name="p_p_lifecycle" type="hidden" value="2" /><input name="p_p_state" type="hidden" value="normal" /><input name="p_p_mode" type="hidden" value="view" /><input name="p_p_resource_id" type="hidden" value="citation-download" /><input name="p_p_cacheability" type="hidden" value="cacheLevelPage" /><input name="p_p_col_id" type="hidden" value="column-1" /><input name="p_p_col_count" type="hidden" value="1" /> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withAbstract"> <input class="checkbox" type="checkbox" name="withAbstract" /> <span class="checkbox-label">Include abstract</span> </label> </div> </form> <iframe title="Citation download frame" name="citation-download-iframe" src="" style="display: none; visibility: hidden" aria-hidden="true"></iframe> </div> </div> </div> </div> <div class="print-modal" style="display: none;" data-modal-title="Print this review"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input title="Select/deselect all" type="checkbox" class="print-options-select-all" checked="checked" /> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i class="fa fa-print" aria-hidden="true"></i> Print</button> </div> </div> <div class="download-stats-data-modal" style="display: none;" data-modal-title="Download statistical data"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <p> Downloaded data can only be viewed using <a class="external" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/tools/review-production-tools/revman-5" target="_blank">Review Manager software.</a> </p> <p> Please note that: <ul> <li>data are only available for Cochrane Reviews that contain one or more forest plots; and</li> <li>data in the downloaded RevMan file are editable and therefore the review data can be amended without warning.</li> </ul> </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input type="hidden" name="content-disposition" value="attachment" /> <input type="hidden" name="mime-type" value="application/octet-stream" /> <p class="print-options-controls"> <input type="checkbox" class="download-stats-data-toc-check-box" aria-label="I agree to these terms and conditions" /> <span class="checkbox-label" aria-hidden="true">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i class="fa fa-download" aria-hidden="true"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" style="display:none;" data-modal-title="Share this review"> <div class="add-this"> <div class="addthis_toolbox addthis_default_style addthis_32x32_style"> <nav class="stacked-nav-list"> <li> <a href="#" class="addthis_button_twitter at300b" title="Tweet">Twitter</a> </li> <li> <a href="#" class="addthis_button_mendeley at300b" target="_blank" title="Mendeley">Mendeley</a> </li> <li> <a href="#" class="addthis_button_facebook at300b" title="Facebook">Facebook</a> </li> <li> <a href="#" class="addthis_button_linkedin at300b" target="_blank" title="LinkedIn">LinkedIn</a> </li> <li> <a href="#" class="addthis_button_email at300b" target="_blank" title="Email">Email</a> </li> <li> <a href="#" class="addthis_button_whatsapp at300b" target="_blank" title="WhatsApp">WhatsApp</a> </li> <li class="clearfix"> <a href="#" class="addthis_button_more btn primary pull-right" target="_blank" title="View more"> <i class="fa fa-plus" aria-hidden="true"></i> View more</a> </li> </ul> </div> </div> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button type="button" class="btn btn-link" id="figureOptionBtn">Figures</button></li> <li class="table-options-btn-container"><button type="button" class="btn btn-link" id="tableOptionBtn">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div id="figureThumbnails" class="figure-thumbnails is-visible"></div> <div id="tableThumbnails" class="table-thumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a href="#" class="figure-viewer-menu-toggle"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-table-show-text="Show table list" data-table-hide-text="Hide table list" data-figure-show-text="Show thumbnails" data-figure-hide-text="Hide thumbnails">Hide thumbnails</span> </a> <a href="#" class="figure-viewer-zoomin"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a href="#" class="figure-viewer-zoomout"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a href="#" class="figure-viewer-nav previous"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a href="#" class="figure-viewer-nav next"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_  portlet-static portlet-static-end kaleo-designer-portlet " id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a title="Cochrane logo" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/">
<img class="footer-logo logo-part-1" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-1.png" alt="Cochrane logo" /> <img class="footer-logo logo-part-2" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-2.png" alt="" /> </a> </div> <nav class="footer-links"> <ul class="root"> <li class="footer-item"> <a class="footer-item-link" href="/about-cochrane1">About Cochrane</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/evidence" target="_blank">Cochrane.org</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank">Who we are</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NJYXT5SPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Get involved</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX665WNWTYE63PMNYXG4DTMFYGKLUQPJUB/" target="_blank">Consumer Network</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-funders-and-partners" target="_blank">Partners</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYXZ5DQPF4XT7LNF3SX8Z5IPJRX63JPN73GH/" target="_blank">Colloquium</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news" target="_blank">In the news</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/publications">Publications</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="/library">Cochrane Library</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/" target="_blank">Library Homepage</a> </li> <li class="footer-item"> <a class="footer-item-link" href="cdsr/about-cdsr" target="_blank">Cochrane Reviews (CDSR)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/central" target="_blank">Trials (CENTRAL)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cca/about" target="_blank">Cochrane Clinical Answers</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/cochrane-library-app" target="_blank">Cochrane Library App</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cdsr/journal-club" target="_blank">Journal Club</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/podcasts" target="_blank">Podcasts</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/community">Community</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Community</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MF3GG4DJMVYGG55DNB3GC5UFF3YYE3D/" target="_blank">Archie log-in</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/PS3GC4LPNFYGPLUDN7SXR6UBN3TT655TMH/" target="_blank">Training and support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/NWTYI4DQMS3T6Z5QMNVHEZLPMVYG86UH/" target="_blank">Methods</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/help" target="_blank">Software</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news/jobs" target="_blank">Jobs and opportunities</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/contact-us">Contact Us</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/contact" target="_blank">General enquiries</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/help/contact-us" target="_blank">Cochrane Library support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/chief-executive-officers-office/team" target="_blank">Chief Executive Officer</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/editorial-methods/team" target="_blank">Editor in Chief</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-global-community" target="_blank">Cochrane groups</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/media" target="_blank">Media</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/accessibility" target="_blank">Accessibility</a> </li> </ul> </li> </ul> </nav> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/advertisers">Advertisers & Agents</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Help & Support</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/terms-and-conditions">Terms & Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright &copy; 2000 - 2020 by <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUYNFXGK8JPMNYXN/" class="">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br /> Review our <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUYNFXGK8JPMNYXN/en-gb/privacy"><strong>Privacy Policy</strong></a> </p> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MW4T675JNSTYTLUDN7XB/"><img class="logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_wiley-footer-logo.png" alt="Wiley logo" /></a> </div> </div> <span class="wiley-semi-circle"></span> </div> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" style="display: none" data-modal-title="Feature in English only" data-modal-class="english-only-modal"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1581422282000" type="text/javascript"></script> <!--<![endif]--> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/theme.js?t=1581422282000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/checkout.js"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MN3G865UNWRYE43NMNTG6LUDPJYYG65TMWUC655TMH/widget/v2.0/widget.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MRZXE8DIHB4XC63SNWYHPN3PMNXG87LEM33G85UVF3YGK7A/assets/embed.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011599\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011599\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011599\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011599\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011599\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581422282000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a href="#" class="rh-nav-close-btn"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a href="#" class="rh-nav-open-btn"> <span>Review tools & navigation</span> </a> </div> <iframe title="Print frame" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" aria-hidden="true"></iframe> <div class="mobile-navigation"> <div class="close-container"> <a href="#" class="main-nav-back-btn" aria-label="Navigate back"><i class="fa fa-chevron-left"></i></a> <a href="#" class="main-nav-close-btn" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="ymag__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011599.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011599.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<a href="/en/browse-by-topic" class="btn secondary">Browse </a>
<a href="/en/advanced-search" class="btn secondary advanced-search-button">Advanced search</a>
</div>
<div class="menu-items parent">
<ul>
<li class="nav-root-item parent">
<a href="#" title="Select language" class="language-selection-title-link">
<span class="mobile-nav-language-title">Select your preferred language</span><span class="icon fa fa-caret-down"></span>
<ul class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="fdkn__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div id="active-content-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div id="active-portal-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="/en/cdsr/doi/10.1002/14651858.CD011599.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD011599.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</ul>
</a>
</li>
<li class="parent">
<a class="mobile-link signin" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011599.pub2%2Freferences" data-redirect="false" rel="nofollow">
Sign In
</a>
</li>
</ul>
<div class="menu-items-footer">
<div class="utility-links">
<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/" class="cochrane-link" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
<div class="basic-login-form-content" style="display: none;" data-modal-title="Sign in">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="dbam__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1583246264536" /> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value="" /> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true" /> <input checked class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onClick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true" /> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user-registration" target="_blank" class="btn secondary">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" style="display: none;" data-modal-title="Institutional login">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="obft__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text">
</div>
<button class="btn primary" type="submit" name="button">Go</button>
</div>
<div id="institutionLookupErrorDiv" class="message error" style="display:none">
'<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
</div>
</div>
<input type="hidden" id="entityId" name="entityId" value="">
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="joiu__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1583246264540" /> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD011599&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value="" /> </div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true" /> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" style="display: none;" data-modal-title="Unlock the potential of Cochrane evidence">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="wpdq__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text"> </div> <button class="btn primary" type="submit" name="button">Go</button> </div> <div id="institutionLookupErrorDiv" class="message error" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input type="hidden" id="entityId" name="entityId" value=""> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'> <input type="hidden" name="openlabel" id="openlabel" value='Open access'> </div> </section> </div> </div>  <script>window.urlTitle="/cdsr/doi/10.1002/14651858.CD011599.pub2";addthis_config={pubid:"ra-593597d01cdf9a55",ui_508_compliant:true};addthis_share={url:window.location.href,title:document.title};</script> <script src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-593597d01cdf9a55"></script> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> </body> </html> 